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SCL subcortical lesions 
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TR repetition time 
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GENERAL INTRODUCTION 
Since Critchley (1929) popularized the concept of "arteriosclerotic parkinsonism", 
many authors have challenged its existence.36,44,55·94·139 Computerized Tomography 
(CT) and Magnetic Resonance Imaging (MRI) have provided support for the concept 
of vascular parkinsonism.57·61'163,166 Atypical parkinsonism (without tremor or levodopa 
response) occurs with subcortical white or gray matter lesions (SCL),57,61·163·166 that 
correlate with arteriolosclerosis, demyelination with loss of axons, and chronic infarcts 
on postmortem studies.18·39,104,121,171 Clinically, vascular parkinsonism ("lower-half'163 or 
'lower-body parkinsonism"57) is dominated by "frontal gait disorder",133 with characte-
ristic shuffling, short steps, start and turn hesitation, variable base (narrow to wide), 
and moderate disequilibrium. 
For obvious reasons authors suggested vascular parkinsonism may represent an 
intermediate stage of Binswanger's disease. Firstly, subcortical lesions are associated 
with frontal gait disorder and dementia, both being symptoms of Binswanger's disease. 
Secondly, the histological findings and the localization of the SCL on MRI are similar 
to those of Binswanger's disease. 
Despite the above mentioned suggestions there are some objections to the 
concept of vascular parkinsonism and the discussion about is particularly hampered 
because of the following reasons. The multiple etiologies of frontal gait disorder133 
make diagnosis of vascular parkinsonism difficult. Moreover, infarction of the basal 
ganglia and deep white matter (or SCL on MRI and CT) occur in elderly people who 
do not have parkinsonism.4,44,52,55,79,88,172 Since some authors were unable to detect 
vascular lesions in patients meeting clinical criteria for idiopathic Parkinson's disease 
(PD),90 the existence of vascular parkinsonism was denied.44,139 
The aim of the present study is to investigate whether patients clinically suspected 
of vascular parkinsonism can be distinguished from patients with idiopathic Parkin-
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son's disease, and whether vascular ischemic lesions can be detected in the former 
patient group. 
The clinical, pathological and metabolical features of vascular parkinsonism and 
Binswanger's disease are reviewed in the introduction (Chapter 1). In this chapter, I 
also discuss the incidence of subcortical lesions on CT and MRI in different patient 
and age groups, their clinical significance, their relationship with vascular risk factors 
and age, their pathological correlates, the hemodynamical and metabolical significance 
of SCL, their pathogenesis, differential diagnosis and its treatment. Furthermore, I 
discuss EEG studies in white matter disease. 
Several authors suggested vascular parkinsonism might be due to subcortical ische-
mia or infarcts. Therefore, we tried to detect metabolic signs (especially elevated 
lactate or decreased NAA) as a reflection of subcortical ischemia and cell loss in 
locations suspected of pathology (i.e. the striatum and deep white matter) which are 
held responsible for the the clinical features of vascular parkinsonism. Therefore !H 
MR spectra of patients suspected of vascular parkinsonism on clinical grounds and 
ischemic score, are compared to proton MR spectra of a control group consisting of 
patients with idiopathic Parkinson's disease (Chapter 2). 
Many attempts have been undertaken to quantify the severity of SCL in order to 
clarify their clinical significance. Until now MR quantification of SCL has been 
performed using semiquantitative rating scales. The main drawbacks of these scoring 
methods are absence of quantitative data on total volume of SCL and moderately 
poor intra- and interobserver agreements of semiquantitative rating scales. The 
purpose of the study desribed in Chapter 3 is to evaluate an efficient stereological 
method for estimating the total volume of SCL and ventricular cerebrospinal fluid 
volumes (VCSF) in living human brain tissue, and to determine its accuracy and 
reproducibility. 
The aim of this study was also to investigate whether MRI can yield evidence for 
vascular lesions in suspected vascular parkinsonism. Therefore, we attemped to 
determine whether: (1) patients who are clinically suspected of vascular parkinsonism 
(SVP) have more SCL on MRI scans than patients meeting clinical criteria for idiopa-
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thic PD; (2) SVP patients have more SCL than hypertensive controls without parkin-
sonism or gait disorder; (3) SCL in SVP patients with an acute onset (SVPa) are loca-
ted differently from SCL in SVP patients with an insidious onset (SVPi); and (4) the 
severity of parkinsonian symptoms in SVP patients is related to the volume and loca-
tion of SCL (Chapter 4). 
Difficulty in walking is thought to be the most important initial symptom in 
vascular parkinsonism. The purpose of the study described in Chapter 5 was to 
investigate whether quantitative gait analysis can differentiate between the gait pattern 
of VP and the gait pattern of PD. To determine which variables of gait are abnormal 
in VP, the gait of the VP group was also compared to neurologically non-diseased 
same-aged controls. Furthermore, the relationship in VP between the severity of gait 
impairment and SCL load on MRI was investigated. 
In Parkinson's disease most conventional and quantitative EEG studies showed 
abnormalities in 35-50% of the cases. Slowing of the occipital background rhythm and 
an increase of activity in the slower frequencies were the most common abnormalities. 
EEG has also been used to detect ischemia. Therefore, we investigated whether pa-
tients suspected of vascular parkinsonism had a different EEG pattern (less EEG slo-
wing, more signs that are related to cerebral ischemia) than patients with idiopathic 
Parkinson's disease {Chapter 6). 
NAA is an aminoacid which is almost entirely confined to neurons. Therefore, we 
tried to detect a metabolic sign (decreased NAA) as a reflection of neuronal cell loss 
in the substantia nigra area of patients with PD, the main locus of neuronal degenera-
tion in PD. MRS might become an important tool to distinguish patients with 
different types of parkinsonism (Chapter 7). 
In Chapter 8 the results of the study are discussed, followed by general indications 
toward future research. 

CHAPTER 1 
INTRODUCTION 
Vascular parkinsonism 
Critchley (1929)33 introduced the concept of 'arteriosclerotic parkinsonism' when he 
proposed that parkinsonism due to vascular disease was a distinctive entity with 
characteristic symptoms and pathologic lesions. Because he did not present clinico-
pathological data, the concept of vascular parkinsonism as a distinctive entity has been 
challenged for decades.36·44,55'139 Computerized Tomography (CT) and Magnetic 
Resonance Imaging (MRI) provided support for the concept of vascular parkin-
sonism.57·61,163,166 Tolosa et al166 and Friedman et al61 related atypical parkinsonism in 
patients without tremor or levodopa response to striatal infarcts on CT. Thompson 
and Marsden163 and Fitzgerald and Jankovic57 in their studies showed a relation 
between parkinsonism and white matter lesions (WML) on CT and MRI. These 
authors suggested vascular parkinsonism might be due to subcortical ischemia or 
infarcts, because WML in postmortem studies are correlated with arteriolosclero-
sis18,39,104,171 d e m y e l i n a t i o n ^ ш ] o s s o f axonslW»,104.121.171.1« a n ( ] c h r o n i c ¿n_ 
farcts.18·39'104,121 Difficulty in walking is the most important initial symptom in the 
patients reported by Thompson and Marsden163 and Fitzgerald and Jankovic.57 There-
fore, vascular parkinsonism is also called lower-half163 or lower-body parkinsonism.57 
Nutt et al133 prefer to use the term frontal gait disorder in these patients, which accor-
ding to them is characterized by shuffling, short steps, variable base (narrow to wide), 
start and turn hesitation and moderate disequilibrium. For obvious reasons it has been 
suggested, that subcortical MRI/CT lesions in the elderly usually represent an inter-
mediate stage of Binswanger's disease. Firstly, because the histological findings related 
to the SCL on MRI and their localization are similar to those described in Binwan-
ger's disease.39,67,96'104,118'144,185 Secondly, because subcortical lesions are associated with 
cognitive decline13·15·20·67,104,168,172 and (frontal) gait disorder,6,57,63,64,79,104,156·163·168 both 
being symptoms of Binswanger's disease. 
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Binswanger's disease 
In 1894 Binswanger9,10 described the clinical course of "chronic progressive subcortical 
encephalitis" (now called Binswanger's disease) characterized by slowly progressive 
intellectual deterioration starting in the sixth decade, with initially impairments of 
memory and associations, apathy and focal deficits; and subsequent agitation, 
paranoia, seizures, disturbances of consciousness, and eventually a decerebrate state. 
Gait in particular was not described in the original article. The neuropathological 
characteristics were atrophy of white matter, especially in the occipital and temporal 
lobes, with only minimal cortical atrophy. The basal and posterior homs of the ventri-
cles were enlarged, whereas the anterior parts of the lateral ventricles were minimally 
expanded. Binswanger suggested that white matter atrophy resulted from deficient 
blood supply caused by arteriosclerosis. Alzheimer in 19021 confirmed the existence of 
the pathological entity, and added the microscopical features of the white matter: 
demyelination and glial proliferation. According to him the changes were caused by 
severe atherosclerosis of the deep white matter long penetrating vessels. He emphasi-
zed sparing of the cortex, subcortical arcuate fibers (U-fibers), and the convolutional 
white matter. Alzheimer,1 like Olszewski134 in his review decades later, also noted 
softenings (lacunes) in the internal capsule, putamen, thalamus, basis pontis and 
cerebellar peduncles. Therefore, Olszewski134 introduced the title "subcortical 
arteriosclerotic encephalopathy". The lacunes are also described without diffuse 
demyelination of the white matter,56 and are therefore considered not pathognomonic 
for Binswanger's disease. Pseudobulbar palsy, gait disorder, extrapyramidal rigidity, 
uni- or bilateral pyramidal signs in the limbs, and focal neurological deficits were 
present in the majority of the cases described in later reviews.5,27 Until 1979 the 
diagnosis of Binswanger's disease depended on post-mortem findings. At that time CT 
became a reliable detector of white matter disease and Rosenberg144 reported the first 
case with pathological verification after CT had shown bilaterally white matter lesions 
in vivo. CT and MRI have been performed in more than 25 cases in which the 
diagnosis of Binswanger's disease has been confirmed at autopsy.39,67,96,104'118,144,185 The 
subcortical lesions observed at autopsy as well as on CT and MRI were most promi-
nent immediately surrounding the lateral ventricles and extended varying distances 
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into the central white matter. There are contempory authors who do not accept 
Binswanger's disease as a distinct clinicopathologic entity.138 In their review about 
Binswanger's disease, Pantoni and Garcia138 concluded that the clinical significance of 
SCL remains insufficiently defined. Many studies are non-controled, based on small 
numbers of patients, and do not take into account associated risk factors. According 
to Caplan,28 Binswanger's disease should not be considered a distinct disease entity. 
The condition probably described by Otto Binswanger (including comments attributed 
to him by Alzheimer) is almost certainly a chronic ischemic disorder of the cerebral 
and cerebellar white matter that has diverse causes and pathophysiologies.28 
Incidence of subcortical lesions on CT 
The incidence of subcortical lesions (leucencephalopathy) on CT dependents on 
patient selection criteria (age and vascular risk factors), and the quality of scans. In 
CT studies the incidence varied from 1.6% to 16% in the elderly.67·104·141·156·168·185 
Subcortical lesions on CT were found in: 1.6% of 1700 patients who also had 
cerebral atrophy on CT scan,168 2.5% of 603 non-selected patients aged 60 to 85 
years,185 4% of 3542 patients from another hospital specialized in cerebrovascular 
disease,67 8% of 1200 patients from a general hospital,67 8% of 65 non-selected 
patients above 60 years,141 8.5% of 105 elderly healthy volunteers,156 and 16% of 89 
cognitively normal elderly without a history of stroke, diabetes mellitus, hypertension 
and/or cardiac disease.63 Both sexes were equally affected.156 
Incidence of subcortical lesions on MRI 
The reported incidence figures of subcortical lesions on MRI are also mainly depen-
dent on patient selection criteria (age and vascular risk factors), terminology of 
lesions, lesion grading, and the different MRI methods used. 
Because MRI is more sensitive than CT in detecting subcortical lesions64'98,104 the 
incidence on MRI is much higher. Hypodense lesions on CT correlate with scattered 
or confluent lesions of increased signal-intensity on T2-weigthed images.64,104 Many 
authors graded the severity of lesions on a 0-3 scale: 0 = no lesions; 1 = focal lesions; 
2 = multifocal lesions, and 3 = confluent lesions.4,15,50,79 In most studies, lesions were 
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also distinguished according their localization; adjacent to the ventricles or in the 
centrum semiovale.4·15·79·82^91·103·104·114:143 
Focal lesions just anterior and lateral to the frontal horns were found in all MR 
scans of 56 patients without central nervous system disease, and were considered as 
normal.160 Confluent lesions were found in 30% of a non-selected group of patients 
over the age of 60 years referred by a neurologist or a neurosurgeon, and in only 5% 
in the group of 41-60 years.4 Multiple focal lesions in these age groups were observed 
in 50% and 30%, respectively. Hunt et al91 found confluent lesions in 8% and multiple 
focal lesions in 20% of 46 subjects above 70 years without major illnesses. Kertesz103 
reported severe periventricular lesions in 26% of acute stroke patients above 60 years, 
and in 15% of healthy volunteers above 60 years. Lechner et al,114 who did not 
distinguish different sizes, found subcortical lesions in 92% of healthy patients (mean 
age: 62 years) with two risk factors for stroke, and in 100% of patients (mean age: 63 
years) with three or more risk factors. Ninety-two percent of the lesions were localized 
in watershed zones. Uhlenbrock and Sehlen,167 Kobayashi et al,108 and Horikoshi et 
al88 confirmed the locations of subcortical lesions in the watershed zones. Van Swieten 
et al170 found the white matter around the anterior horns and the posterior cella 
media of the lateral ventricles, and the posterior part of the centrum semiovale to be 
frequently lesioned. Both sexes were equally affected.4 
Clinical significance of subcortical lesions on CT 
In most CT studies subcortical lesions were associated with age,63,67,84,156 gait distur-
bance,57·63·104·156·163·168 dementia,67·104·168 urine incontinence,67·104·168 risk factors for 
arteriosclerosis,67·104·168 and stroke.84·92 Dementia occured in 22% of 152,67 in 78% of 
of 23,104 and in 68% of 28168 patients with subcortical lesions on CT. Gait disturbance 
was found in 22% of 23,104 in 22% of 9,156 and in 54% of 28 patients168 with subcorti-
cal lesions on CT. Gait disorder 57,163 was the main presenting symptom in some stu-
dies, dementia in others.67,104·168·185 Urine incontinence has been reported in 25% of 
152,67 in 22% of 23,104 and in 18% of 28168 patients with subcortical lesions on CT. 
Pseudobulbar palsy was found in 16% of 15267 patients with subcortical lesions on CT. 
Kinkel et al104 clearly showed that subcortical CT lesions can be asymptomatic. 
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Hypertension occured in 93% of 152,67 in 78% of 23,104 and in 71% of 28168 patients 
with subcortical lesions. Diabetes mellitus was found in 10% of IO,67 and in 17% of 
23104 patients with subcortical lesions. Inizitari et al92 could not find an association 
between subcortical lesions on CT and diastolic bloodpressure, myocardial infarction, 
angina, diabetes mellitus or carotid bruits in patients mainly with dementia. Further-
more, they showed with logistic regression analysis that a history of stroke was the 
single most powerful predictor of subcortical lesions. Hypertension alone did not 
improve the prediction of these lesions in their patients. Apart from increasing age, 
Hijdra et al84 demonstrated with logistic regression analysis that the presence of 
lacunar infarcts is the most important determinant of subcortical lesions. Hypertension 
was not an independent variable when the type of cerebral pathology (lacunar infarct) 
was taken into account. Therefore, they suggested that subcortical lesions on CT are 
predominantly associated with small vessel disease. Schneider et al150 demonstrated 
that subcortical lesions were related to highly elevated plasma viscosity. 
Clinical significance of subcortical lesions on MRI 
In most MRI studies subcortical lesions were associated with age,15,51·64'79'91 cognitive 
impairment or dementia,13'15,20105·172 gait disturbance,6,57,79 risk factors for arterioscle-
rosis in general,4,15,51,114 strokes,103 hypertension alone,4,103,116,172 diabetes mellitus,149 
heart disease,20,116 high cholesterol levels,19 and high fibrinogen levels.20,28 
Some authors reported that in the elderly population SCL are associated with 
neuropsychological deficits,13,15,105,172 while others could not find a relationship 
between these lesions and cognitive abnormalities.79,91,143 This contrast can be explai-
ned by the fact that, in the majority of studies that failed to find any association, tests 
of overall cognitive functioning (e.g. dementia screening examinations)79 were used, 
the patient group was too small91 or the presence rather than the severity of lesions143 
had been scored. 
SCL on MRI can be asymptomatic,88,172 even when they are large and confluent. 
Van Swieten et al172 reported of 3 out of 10 hypertensive patients with confluent 
lesions who performed well in daily life as well as on neurolopsychological testing. 
One of 14 patients above 70 years with risk factors for arteriosclerosis, who had no 
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previous history or signs of a neurological disorder, showed widely confluent lesions.88 
Three of them had partial confluent lesions. 
Hypertension occured in 80% of 25 patients with stroke and SCL, whereas in 
significantly less patients (56%) with stroke and without SCL.103 Boone et al13 could 
not Gnd a significant relationship between cholesterol levels and subcortical lesions.13 
Diabetes mellitus was found in 36% of 25 patients with SCL,103 and in a not signifi-
cantly different number of patients (25%) with strokes without SCL· According to 
Awad et al4 prior brain ischemia and hypertension are the major predictors of SCL in 
the elderly, whereas diabetes and coronary artery diseases do not play a significant 
role. 
Hemodynamical and metabolical significance of subcortical lesions 
The regional cerebral blood flow was found reduced in the lesioned white matter of 
neurological nondiseased subjects,51105·106'123,125,161'181182 as well as in the lesioned white 
matter of patients with dementia,102,105·106'118·125'161'181·182 or gait disturbance;118·181 using 
Xenon enhanced computed tomography102·105'106·118·125·161 or PET scan techni-
que51'123,181'182. Kobayashi et al,108 in a study with Xenon enhanced computed tomo-
graphy, reported that there was no significant diference in cerebral blood flow 
between healthy subjects with and without apparent subcortical lesions. But they con-
cluded that their subjects had a milder grade of subcortical lesions than patients 
examined in other studies. 
As in patients with acute subcortical infarctions,112 a reduction in the regional 
cerebral blood flow was also found remote from the subcortical lesions on CT or MRI 
scans: in the caudate nucleus,102·106·161 putamen,102·106·161 internal capsule,102-106·161 
thalamus,102·161 and in the parietal,102·106'161·181 frontal,102·106·181 temporal,102·106·161'181 and 
occipital102,161 cortices. 
Meguro et al123 reported reduced cerebral blood flow in their neurological non-
diseased patients with subcortical lesions, although oxygen metabolism was not 
measurably affected. They observed an increased oxygen extraction factor, indicating 
that misery perfusion exists in these patients. Yao et al181 also observed a normal 
oxygen metabolism and an increased oxygen extraction factor in non-demented pa-
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tients with subcortical lesions. However, in demented patients with subcortical lesions 
the oxygen metabolism and the oxygen extraction factor were decreased. Therefore, 
they assumed that misery perfusion exists in the white matter at the very early stage 
of white matter disease. 
Using PET scan technique, Mielke et al127 found impairment of glucose metabo-
lism in the temporal and frontal association cortex, basal ganglia, thalamus and cere-
bellum of their patients with dementia due to mainly subcortical lesions. The volume 
of metabolic impairment was significantly related to the severity of dementia. 
Sappey-Marinier et al146 could not detect MRS signs of ischemia (increased 
lactate), or signs of neuronal cell loss (reduced NAA) in the brains of 5 patients with 
subcortical lesions. Two of them had global cognitive impairment. 
EEG in subcortical lesions 
In their review about Binswanger's disease, Babikian and Ropper5 collected 27 
pathologically verified cases in whom EEG was recorded. In 52% of the patients, the 
EEG was characterized by diffuse background theta and delta slowing. Predominantly 
focal or asymmetric slowing was seen in 11% of cases, especially over the temporal or 
frontal areas.8,24'144 In the two patients with serial EEG's, focal changes were oversha-
dowed by generalized background slowing as the disease advanced.24,144 In one patient 
periodic activity with sharp and slow wave complexes was reported.177 Normal EEG's 
were observed in at least 2 longstanding cases.27,35 
Parkes et al139 found a considerable excess of slow frequencies in patients 
suspected of vascular parkinsonism. In contrast, Tolosa et al166 reported a normal 
EEG in their 2 patients suspected of vascular parkinsonism. But, in these patients, 
parkinsonism was probably caused by lacunar infarcts in the striatum, and not by 
white matter disease. 
Pathogenesis of SCL, three main hypotheses 
1/ Many hypotheses about the pathogenesis of subcortical lesions exist. The explana-
tion originally proposed by Binswanger and Alzheimer1,9,10 that the white matter 
softening can be attributed to chronic ischemia as a result of arteriolosclerosis of the 
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long penetrating arteries, remains the most supported hypothesis. According to this, 
arteriolosclerosis of these end arteries, which are poorly provided with collateral 
anastomoses, results in ischemia of the distal fields of these vessels, i.e. periventricu-
larly and in the watershed zones. 
At least three arguments support this view. Firstly, 94% of 72 pathologically 
confirmed cases had hypertension,5 one of the main causes of arteriolosclerosis. 
Likewise, subcortical lesions in most MRI and CT studies are correlated with hyper-
tension.67'103,104'168 Secondly, the localization of white matter lesions observed at 
autopsy and on MRI and CT corresponds with the watershed zones and the arterial 
end zones of the deep penetrating vessels.9·36·88·108'114'134·167·170 Finally, Yao et al182 and 
Meguro et al123 observed an increased oxygen extraction factor in non-demented pa-
tients with subcortical lesions on MRI, assuming that misery perfusion exists in these 
patients. 
In line with this view, transient episodes of hypotension caused by excessive 
antihypertensive medication or heart failure,20,116 as well as hyperviscosity150 may 
provoke or aggravate white matter disease in an already compromised cerebral blood 
flow.23,27,37,119,122,144,165 Serum viscosity depends mostly on the hematocrit and fibrino-
gen levels.71,162 Indeed, fibrinogen levels were significantly higher in the group with 
marked white matter lesions than in those without.20,28,150 The contribution of the 
extracranial arterial disease to subcortical lesions is still controversial.29,50,82,157 
2/ Another hypothesis was proposed by Feigin et al,54 who attributed the high 
incidence of white matter lesions in hypertensive patients to brain oedema, leading to 
hypoxia, cell loss and gliosis. According to these authors, subcortical lesions might 
reflect a slight increase in interstitial water caused by hypertension and vascular 
damage with leakage of fluid into the extracellular space.189 But the selective involve-
ment of white matter in Binswanger's disease due to hypertension is inconsistent with 
the finding of Byrom25 asserting that in acute experimental hypertension, gray matter 
is the site of damage. The same author also emphasized that in rats, symptoms 
completely disappeared only hours after hypertension was discontinuated. This 
suggests that cell loss by oedema due to hypertension can not be the only cause of 
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subcortical lesions. Furthermore, all the pathologically studied cases described by 
Caplan and Schoene27 showed prominence of thickened vessels in the white matter. In 
contrast, not all patients had hypertension, thereby suggesting that the essential 
pathologic change is thickening of long penetrating cerebral arteries, arterioles, and 
capillaries, usually related to hypertension, but in some cases possibly related to 
atherosclerosis caused by other vascular risk factors. 
3/ Some investigators postulated that white matter lesions could be due to ventricular 
enlargement. Bradley et al16 found a significant association between subcortical lesions 
and ventricular enlargement. Caplan et al27 reported one patient with Binswanger's 
disease who improved after ventricular shunting, while another patient improved 
following removal of cerebrospinal fluid.24 In 81% of 47 pathologically verified cases 
of Binswanger's disease reported in the literature, the lateral ventricles were modera-
tely or greatly enlarged.5 Bradley et al16 and Earnest et al46 suggested that ventricular 
enlargement in at least some cases may be caused by a number of different ischemic 
insults, leading to decreased periventricular tensile strength. Others postulated that 
the subcortical lesions are caused by the ventricular enlargement which might result in 
transependymal movement of cerebrospinal fluid into the interstitium of the periven-
tricular parenchym.41,189 But this last view is inconsistent with the finding that ventri-
cular enlargement is not seen with mild degrees of Binswanger's disease.104 
Differential diagnoses of Binswanger's disease 
The differential diagnoses of Binswanger's disease include: 1/ other diseases accom-
panied by frontal gait disorder with asymptomatic SCL - different types of parkinso-
nisms; 2/ other diseases accompanied by dementia with asymptomatic SCL - Alzhei-
mer's disease, cerebral amyloid angiopathy, thalamic or hypocampal damage, cerebral 
oedema with tumor; 3/ superficial cerebral infarction with mainly white matter 
damage; 4/ dilated perivascular spaces; 5/ normal pressure hydrocephalus with 
subcortical lesions adjacent to the ventricles resulting from transependymal passage of 
cerebrospinal fluid; 6/ unrelated white matter disease - multiple sclerosis, lymphoma, 
post-infectious encephalomyelitis, etc.; 7/ radiation effect; 8/ methotrexate white mat-
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ter necrosis; 9/ antiphospholipid antibody syndrome; 10/ CADASIL, cerebral autoso-
mal dominant arteriopathy with subcortical infarcts and leucoencephalopathy.14·28,56'104 
Treatment 
No curative therapy has been reported. Moreover, no prospective study about a 
therapy that prevents progression is published. So, virtual treatment should include 
careful blood pressure control (treatment of heart failure, careful administration of 
antihypertensive medication), as well as management of other factors that may affect 
white matter disease (e.g., blood sugar, red blood cell volume and antiñbrinogen 
therapy150). It remains controversial whether desobstruction in extracranial arterial 
disease29,50·82 or shunting when ventricular enlargement is present46,56 are of great 
benefit to some patients with subcortical lesions. 
CHAPTER 2 
Proton Magnetic Resonance Spectroscopy in 
Suspected Vascular Ischemic Parkinsonism 
Zijlmans JCM, de Koster A, van 't Hof MA, Thijssen HOM, 
Horstink MWIM, Heerschap A 
Acta Neurol Scand 1994;90:405-411 
INTRODUCTION 
Since Critchley drew the attention to the concept of "arteriosclerotic parkinso­
nism"33 in 1929 many authors have challenged its existence.36,44,55,94,139 
Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI) yielded 
more clues for the existence of vascular parkinsonism (VP).57,61,163166 The subcortical 
lesions (SCL) on MRI or CT scans suggest that vascular parkinsonism might be due 
to subcortical ischemia or lacunar infarcts.57,163 Fitzgerald and Jankovic57 propose that 
the subcortical ischemia is of chronic nature. Because difficulty in walking is the most 
important initial symptom,57·163 vascular parkinsonism is also called lower-half163 or 
lower-body parkinsonism.57 
In patients with cerebrovascular disease proton MR spectroscopy (MRS) showed 
lactate (Lact) elevation and loss of N-acetylaspartate (NAA) in acute and chronic 
infarcted regions.7,19,65,69,81,146 Increased lactate is also a useful marker of ischemia in 
ischemic noninfarcted brain.7 The lactate level was also found to be above normal in 
the subacute phase of stroke with hyperemia, suggesting lactate production through 
aerobic glycolysis.81 Although NAA is accepted as a neuronal marker,109 its specific 
role is still unknown. There appears to be a relation between reduced NAA and 
neuronal cell death.19 
Two other striking metabolite peaks observable in an in vivo Ή MR spectrum of 
the brain are the trimethylamines (TMA) peak and the creatine plus phosphocreatine 
(labeled as Cr) peak. The principal contributors to the TMA signal are choline-contai-
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ning compounds.128 Although free brain choline rises with brain ischemia151 in rat, the 
choline signal did not change significantly in most human JH MRS studies of acute or 
chronic stroke.7,19,69,81 The Cr signal is frequently used as an internal standard to 
calculate ratios with other metabolites (NAA/Cr, TMA/Cr, Lact/Cr), because Cr shows 
a relatively stable intensity during disorders of cell metabolism.107'140,152 
In earlier studies the feasibility of lH MRS examinations of the striatum in 
patients with idiopathic Parkinson's disease (PD) was demonstrated.34,78,86 None of the 
main resonances, NAA, TMA and Cr, observed in the !H MR spectrum of the stria-
tum in PD patients showed significant differences with control spectra.34,78,86 
The goal of the present study is to detect metabolic signs (especially elevated 
lactate or decreased NAA) as a reflection of subcortical ischemia and cell loss in 
locations suspected of pathology (i.e. the striatum and deep white matter) which are 
held responsible for the clinical features of vascular parkinsonism. Therefore, 1H MR 
spectra of patients suspected of vascular parkinsonism on clinical grounds and ische-
mic score, are compared to proton MR spectra of a control group consisting of pa-
tients with idiopathic Parkinson's disease. 
MATERIAL AND METHODS 
Fifteen PD patients (10 men, 5 women) and 12 patients suspected of vascular 
parkinsonism (SVP) (7 men, 5 women) were examined after informed consent was 
obtained. PD was diagnosed in accordance with specific diagnostic criteria.90 Four PD 
patients had levodopa medication. Suspected vascular parkinsonism was diagnosed in 
case of levodopa-resistant parkinsonism which is mainly located in the lower body; 
together with subcortical lesions on MRI, and an abnormal ischemic score (see 
below). Patients with multiple system atrophy,142 progressive supranuclear palsy,94 or 
any other obvious cause of parkinsonism94 were excluded in accordance with appro-
priate clinical standards.94,142 Patients with non-parkinsonian neurological diseases, 
except Transient Ischemic Attacks (TIA) or Reversible Ischemic Neurological Deficit 
(RIND), were also excluded, as well as patients with cognitive impairment (Mini 
Mental State Examination <23)58 and patients unable to walk for 25 meters. 
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All patients were evaluated in accordance with the criteria of Loeb and Gandol-
fo's117 modified version of Hachinski's ischemic score.76 This score is normally used to 
evaluate the differential diagnosis between Alzheimer's disease and vascular dementia. 
The score ranges from 0 to 10 points. If the total score is two points or less a 
neurodegenerative cause is considered, if the score is 5-10 points the cause is probably 
vascular,117 and if the score is 3 or 4 points the cause remains unsettled. For the 
detection of subcortical lesions we used MR images made with a spin-echo sequence 
SE PDW-T2W (TE 20-80 msec; TR 2000 msec), instead of CT scans. Because MRI is 
more sensitive to subcortical lesions than CT64 we adapted the score for this item. 
Isolated lesions on MRI scans were not counted, because they occur in the majority of 
the normal elderly15,51'149 and therefore were regarded as not discriminating. Multiple 
confluent lesions were scored 3 points (see figure 1 for representative confluent 
TMA Creatine 
Figure 1. The upper spectrum is obtained from the deep white matter in the only one patient who showed 
lactate during examination, 1 week after a transient ischemic attack. The lower spectrum is from the same 
patient in the same location, 5 weeks later. The lactate is reduced TMA, trimethylamines; NAA, N-
acetylaspartate. The MRI-scan (SE PDW) shows the specific volume of interest and representative multiple 
confluent lesions. 
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Figure 2. Spectrum obtained from the striatum of the same patient as in figure 1, one week after 
a transient bchemic attack. No lactate was found. The MRI-scan (SE PDW) shows the specific 
volume of interest and representative multiple focal lesions. See figure 1 for explanation of 
abbreviations. 
lesions) and multiple focal lesions 2 points (see figure 2 for representative focal le-
sions) (cf. van Swieten et al.170). All SVP patients had an ischemic score of 3 or more 
points, ten patients even had an ischemic score of 5 or more points. The maximum 
ischemic score in our PD patients was only 2 points. 
In all patients, PD and SVP, the severity of their clinical syndrome was expressed 
in gait velocity because gait disorder is the main subject of our study, being the most 
prominent symptom in vascular parkinsonism. The velocity of gait during free speed 
walking was assessed by measuring the time needed to cover a distance of ten meters. 
See table 1 for mean age, ischemic score, SCL subscore, duration of gait disorder and 
gait velocity. 
MR spectroscopy was performed on a 1.5 tesla Magnetom SP63 (Siemens, Erlan-
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gen, Germany). The standard circular polarized head coil was used. Scout images in 
the sagittal, axial and coronal orientations were made to select the volume of interest 
for localized single volume 1H MRS. In our patient group the SCL were most fre-
quently seen in the striatum and the fronto-parietal deep white matter, as described 
by others,57,61,163·1*6 so both the striatum and the fronto-parietal deep white matter are 
chosen for MRS examination. In 9 PD and 6 SVP patients the striatum was selected 
with a volume of 2x2x2 cm. In 6 PD and 7 SVP patients a volume of 4x2x2 cm was 
located in the fronto-parietal deep white matter, while in 1 SVP patient both locations 
were selected. Among the patients the selection between the striatum and the fronto-
parietal deep white matter, was at random. In some cases the SCL did not fill the 
volume of interest fully, so a partial volume effect on the anatomical level could be 
expected. However, since it has been shown102,161 that the cerebral blood flow is also 
Table 1. Patient characteristics 
SVP patients PD patients 
(n=12) (n=15) 
Mean±SD Mean±SD 
70±3 57±13 
5.2±1.3 0.3±0.7 
3.6±3.3 3.9±2.6 
73±17 83+36 
2.8±0.4 0.3+0.7 
*: Loeb and Gandolfo117 
Age (years) 
Ischemic Score (0-10 points)* 
Duration of gait disorder (years) 
Velocity of walking (cm/s) 
SCL score (0-3 points) 
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significantly reduced remote from SCL, the partial volume effect in those cases can be 
considered to be low on the metabolic level. In all examinations the volume of interest 
was located contralateral to the side of the body with the most severe parkinsonian 
symptoms. 
Global and volume-selective shimming of the magnetic field was performed. In all 
examinations the spectral linewidth at half height of the water signal was less than 7 
Hz for the striatum, or less than 5 Hz for the deep white matter. 
Proton MR spectra were acquired with a double spin echo sequence, by which the 
volume is delineated with three frequency selective radiofrequency pulses in the 
presence of linear BO gradients, and a chemical shift selective (CHESS) pulse to 
achieve water signal suppression.75 The repetition time (TR) was 2500 msec and the 
number of acquisitions 260; An echo time (TE) of 135 msec was chosen. At this TE 
signals of triglycerides co-resonating with lactate signals will be strongly reduced and 
the lactate signal will appear in antiphase as a doublet with a 7 Hz J coupling which 
enables its distinction from other signals. 
All NMR data were transferred to a SUN computer (SPARC Station 330, Mo-
del 547, SUN Microsystems, Mountain view, California) and processed with NMR1 
software (New Methods Research, Syracuse, NY). Data processing contained zero-
filling of the free induction decay to 2048 data points, exponential multiplication, 
Fourier transformation and curvefitting to a Lorentzian line shape. Peak area ratios of 
NAA, TMA and Lact with respect to Cr, as well as estimated absolute concentrations 
of these metabolites were evaluated. The absolute concentrations of NAA, TMA and 
Cr were calculated with water as an internal standard,164 using the estimated T2 
relaxation times of the methyl proton spins of these metabolites and of the proton 
spins of water in the striatum (NAA: 340 msec; TMA: 320 msec; Cr: 200 msec; water: 
75 msec)59·175 and the deep white matter (NAA: 320 msec; TMA: 270 msec; Cr: 240 
msec; water: 75 msec).32,131,175 These estimated T2 relaxation times of TMA, Cr, NAA 
and water were in accordance with the T2 relaxation times measured in two of our 
patients and three healthy volunteers, when using a double spin echo sequence (TR: 
3000 msec and 5 different echo times, TE: 35-810 msec). In one patient with elevated 
lactate the T2 relaxation time of the methyl proton spins of lactate in the deep white 
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matter was estimated to be 250±75 msec, using the same double spin echo sequence 
described as above. Echo times generating maximum lactate signal amplitudes were 
selected for this purpose. This T2 value is in accordance with the estimation of Sap-
pey-Marinier et al.,146 who reported that the T2 relaxation time of the methyl proton 
spins of lactate in a patient with a chronic infarct was 225 msec. For the calculation of 
tissue concentrations (mMol/1 tissue) the water content of the adult human brain was 
assumed to be 85% for the striatum and 73% for the white matter in relation to pure 
water.153 Although these values may be different in edema, we applied the same 
values to PD and SVP because there is normally no edema in PD in the regions of 
interest, neither are such abnormalities seen on MRI in our PD patients. In patients 
with SVP edema could be present. However, according to Narayana et al.131 the 
average water concentration in the voxels of our patient groups will not differ more 
than 10% from the water concentration in a voxel containing normal cerebral tissue. 
Statistical analysis was performed by two way ANOVA and multiple regression analy­
sis. 
RESULTS 
Figure 1 shows a MRI-scan of a SVP patient indicating the volume of interest for 
MR spectroscopy in the deep white matter. It also shows the 1H MR spectra from this 
volume. Peaks corresponding to NAA and other N-acetylated compounds at 2.03 
ppm, Cr at 3.02 ppm, and TMA at 3.20 ppm are readily apparent. The spectra shown 
are from the only SVP patient who had a small lactate signal in the spectrum. Except 
for the lactate signal these spectra are representative for both patient groups. This 
patient had two examinations in the deep white matter, one and six weeks after a TIA 
(figure 1). Using a double spin echo sequence with a TE of 135 msec the signal of the 
methyl group of lactate is observed as an inverted doublet with a splitting of 7 Hz at 
1.3-1.4 ppm. It is clearly shown that the lactate signal is reduced between the two 
examinations. 
Peak area ratios and estimated concentrations of the MRS observable metabolites 
(NAA, Cr, TMA) in the striatum and the deep white matter of PD and SVP patients 
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are given in table 2. Because a lactate signal was detected in only one SVP patient the 
Lact/Cr peak area ratio and the lactate concentration were not used for statistical 
analysis. 
In the patient who showed lactate in his spectrum the Lact/Cr peak area ratio one 
week after the TIA was 0.4, five weeks later 0.2; and the corresponding estimated 
lactate concentration one week after the attack was 1.6 mM, five weeks later 0.8 mM. 
During the first examination of this patient there also was a spectrum obtained from 
Table 2. Peak area ratios and estimated metabolite concentrations in the striatum 
and the deep white matter of PD and SVP patients 
Location: Striatum Deep white matter 
SVP PD SVP PD Signi-
patients patients patients patients ficance 
(n=6) (n=9) (n=7) (n=6) level1 
NAA/Cr ratio 
TMA/Cr ratio 
NAA(mM) 
Cr(mM) 
TMA(mM) 
Mean±SD 
1.5 ±0.3 
1.0±0.3 
8.0+1.6 
7.0±1.2 
1.9±0.6 
Mean ± SD 
1.4+0.2 
0.9±0.2 
8.3 ±2.0 
7.0±1.2 
2.0±0.6 
Mean±SD 
1.7±0.2 
0.9±0.2 
8.5±2.4 
5.5 ±1.6 
1.6±0.8 
Mean±SD 
1.7±0.2 
0.9+0.2 
9.9±1.6 
6.8±2.0 
2.0±0.6 
ns 
ns 
ns 
ns 
ns 
NAA N-Acetylaspartate; TMA trimethylamines; Cr: creatine; 
SVP: suspected of vascular parkinsonism; PD: Parkinson's disease, 
ns: not significant, p> 0.05. 
': significance level between patient groups, two way ANOVA after correction for 
location. 
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the striatum, which did not show a detectable signal for the methyl group of lactate 
(figure 2). MR spectra obtained from the deep white matter and the striatum of the 
other eleven SVP patients and all PD patients did not show any lactate signal. 
To investigate whether there are spectral differences between the two patient 
groups, two way ANOVA was applied while correcting for the location (striatum or 
deep white matter). There were no significant differences between PD and SVP 
patients regarding all examined metabolite ratios and estimated concentrations (all 
ρ > 0.05, table 2). 
Multiple regression analysis showed that the metabolite peak area ratios and 
concentrations were not significantly influenced by age, sex, levodopa medication, 
duration of gait disorder or severity of gait disorder (all p>0.05). 
DISCUSSION 
A problem with MR spectra obtained with acquisition methods based on spin 
echoes is, that part of a detected spectral change may be the result of changes in the 
T2 of metabolite proton spins instead of a change of metabolite proton spin concen­
tration. A Tl influence in our examinations is expected to be negligible59 because of 
the fairly long repetition time (TR) used. T2 effects can be taken into account by 
measuring the proton T2's of MRS visible metabolites in all individual patients, which 
then can be used to estimate absolute concentrations. However, for most patients T2 
measurements are too time-consuming to be acceptable. For estimation of the 
absolute concentrations the T2 relaxation times reported in studies with healthy adults 
were used,59,131,175 since we obtained similar values in two patients and three volun­
teers (unpublished data). Furthermore Ott et al136 did not find different T2 values in 
the basal ganglia of PD patients and healthy volunteers; and Sappey-Marinier et al146 
have reported that the proton T2 relaxation times of the metabolites were not signifi­
cantly different between normal subjects and patients with SCL.146 Likewise Gideon et 
al65 reported that the T2 relaxation times of the three metabolites and water in acute 
cortical infarcts did not differ significantly from these measured in a control group. 
Furthermore, for accurate quantification of the metabolite concentrations a good 
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signal linearity with the amount of metabolites and good volume selection avoiding 
signals from the brain tissue outside the volume of interest is necessary. In a series of 
phantom studies using water solutions of NAA at different concentrations within the 
biological range we found an excellent linearity of the NAA signal with selected 
volume size from 27 cc down to 3.4 cc. Furthermore, phantom studies showed less 
than 5% contamination by signals outside the selected volume. 
No lactate signal was observed in 6 of the 7 SVP patients examined in the deep 
white matter, and not in any SVP patient examined in the striatum either. The small 
lactate signal detected in the deep white matter of only one SVP patient was probla-
bly caused by a TIA one week before the first and six weeks before the second 
examination. The other 11 SVP patients and all PD patients did not have a TIA or a 
RIND during one year before the examination. 
The in vivo lactate concentrations in the brains of healthy adult individuals 
reported in literature are about 0.5 mM or less.7,60'77,146 In 4 healthy volunteers we 
found variable lactate levels in the deep white matter (detected in volumes of >60 cc), 
the highest lactate concentration found was about 0.7 mM. From the second spectrum 
obtained in our TIA patient showing lactate, we estimated that the detection limit of 
the methyl signal of lactate for spectra obtained from the 16 cc volume of interest in 
the deep white matter will just be below ±0.5 mM. It follows that for the 8 cc volume 
of interest in the striatum this detection limit is probably about 2 mM with the same 
acquisition time and parameters used. Therefore a small elevation in lactate will go 
undetected in the striatum, whereas it may be detected in deep white matter. Still 
these are low figures in comparison with the reported lactate concentrations of 5-16 
mM in acute cortical infarcts.7,19 As far as we know absolute lactate concentrations in 
acute or chronic subcortical stroke have not yet been reported. Dilution by oedema 
could be a cause for the absence of detectable lactate concentrations. This is not 
probable in our study because the other metabolite peak area ratios and concentra-
tions were not different from those found in studies with healthy individuals (see 
below). Therefore we conclude that as matters stand at present MRS can not detect 
chronic ischemia in the deep white matter of patients suspected of vascular parkinso-
nism. Furthermore in the striatum severe chronic ischemia with the severity and extent 
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already described in infarcts ' can be excluded in our patients. This is in accordance 
with the conclusion of Sappey-Marinier et al,146 who could not detect lactate elevation 
in patients with subcortical lesions. 
A possible explanation of these results could be that vascular parkinsonism is due 
to acute ischemic attacks resulting in neuronal cell loss, while later on lactate normali-
zes by diffusion and active transport. However, cell loss does not seem to be in 
accordance with our spectroscopic results, because the NAA/Cr peak area ratios and 
NAA concentrations, as well as the TMA/Cr peak area ratios and TMA and Cr con-
centrations did not show significant differences between PD and SVP patients, even 
when we ruled out the influence of age, sex, medication, duration of gait disorder, 
severity of gait disorder and the volume of interest (fronto-parietal deep white matter 
or striatum). A decrease of peak area ratios and concentrations in both disorders 
compared to healthy individuals can be an argument for these insignificances. This is 
probably not the case, because the striatum and deep white matter do not show a 
significant neuronal cell loss in postmortem studies concerning PD.94 Furthermore 
NAA/Cr peak area ratios and estimated NAA concentrations as measured by us in 
both groups are comparable with the NAA/Cr peak area ratios22 and NAA concentra-
tions in healthy individuals, described by the majority of authors.32·43·78·80'86'111'126 
Arnold suggested that NAA may be a marker of neuronal function loss besides of 
neuronal cell loss.3 In this case the NAA concentration in both striatum and deep 
white matter in PD and SVP patients could have been decreased. This also does not 
seem to be probable, because of the similarity between the NAA/Cr peak area ratios 
and NAA concentrations found in our patients and those reported in healthy indivi-
duals.22*32·43'78,80,86'126 Therefore we conclude that we can not find metabolic signs 
associated with neuronal cell loss or neuronal dysfunction in our SVP patients as far 
as NAA is concerned. This is in accordance with the conclusion of others, who also 
could not detect changes in the NAA concentrations in patients with subcortical le-
sions.146 
In conclusion, with the actual knowledge and MRS methods of this moment we 
could neither demonstrate metabolic evidence for the existence of ischemia (increased 
lactate, as detectable in our only one patient with acute ischemia), nor of neuronal 
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cell loss (decreased N-acetylaspartate) in our patients suspected of vascular parkinso-
nism. This means that clinically significant ischemia is probably not present in our 
patients, or that the metabolic signs of ischemia and cell loss are too subtle to be 
detected by the presently used MRS method. In the latter case, other methods such as 
perfusion studies may be needed to identify vascular parkinsonism. 
CHAPTER 3 
MR volume estimation of subcortical brain lesions and 
ventricular cerebrospinal fluid: a simple and accurate 
stereologic method 
Vogels OJM, Zijlmans JCM, van 't Hof MA, Thijssen HOM, Horstink MWIM 
Am J Neuroradiol 1995;16:1441-1445 
INTRODUCTION 
With the advent of brain Magnetic Resonance (MR) imaging subcortical white 
and gray matter lesions (SCL) have been identified in healthy subjects, and in a 
variety of neurological diseases and sequelae of general interaal diseases.135 The 
clinical significance of SCL is subject to controversies regarding their pathogenesis. 
Many attempts have been undertaken to quantify the severity of SCL in order to 
clarify this issue. Until now MR quantification of SCL has been performed using 
semiquantitative rating scales.4·15'49,79,1'17'184 The main drawbacks of these scoring me-
thods are: (1) absence of quantitative data on total volume of SCL; (2) consequently, 
unreliable information concerning the actual severity of SCL; (3) moderately poor in-
tra- and interobserver agreements of semiquantitative rating scales.115,147,184 
The purpose of this study is to evaluate an efficient stereological method for 
estimating the total volume of SCL and ventricular cerebrospinal fluid volumes 
(VCSF) in living human brain, and to determine its accuracy and reproducibility. 
METHODS 
Subjects 
As part of a larger study towards a refinement of clinical criteria of suspected vascular 
parkinsonism (unpublished data) three patients with idiopathic Parkinson's disease, 
seven patients suspected of vascular parkinsonism (i.e. lower body parkinsonism, ab-
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sent response to levodopa, and abundant SCL on MR) and two hypertensive control 
patients were randomly selected from a large patient population to assess the accu­
racy of the volume quantification method. 
Stereological quantification method 
MR examination was performed with a 1.5 tesla Magnetom using MR pulse sequence 
parameters 2500/20/2 and 2500/80/2 (repetition time/echo time/excitations). Images 
were made in the transverse plane, parallel to the intercommissural line, throughout 
the whole brain. Slice thickness was 4 mm with a 0.4 mm interslice gap. Spatial resolu­
tion was 0.9 mm, corresponding to a 256 χ 256 matrix. All MR scans had an identical 
field of view of 230 mm. 
To determine the interobserver random and systematic error, two investigators 
(O.J.M.V., J.C.M.Z.) quantified separately the total volume of SCL as evident from 
areas with increased signal intensity on both 2500/20 and 2500/80 images, without 
knowledge of age, gender, identity, or clinical diagnosis of the patients. Perivascular 
dilatations (Virchow-Robin spaces) were not taken into account, because they are 
isointense relative to CSF on SE PDW images.17 A hyperintense rim around the tip of 
the frontal horn was present in all subjects, and was considered normal. Actual 
volume measurements were performed on proton density weighted images (2500/20). 
To determine intraobserver random error, one investigator (J.C.M.Z.) quantified 
SCL and VCSF volumes twice with an interval of 4 weeks, again without knowledge of 
age, gender, identity, or clinical diagnosis. 
For volume determination the digital image information was not transferred onto 
an image analysis system, nor was the MR-slice analysed on the computer screen as 
the latter gives erroneous results due to the parallax of the computer screen itself. 
Instead, the photographic hardcopy of each MR-slice was used. The magnification 
factor of each hardcopy is defined as the actual length of the scale bar of each MR-
slice divided by the representing length of brain tissue, in this study 43.48 mm /100 
mm = 0.4348. 
For SCL volume determination each MR-slice was linearly magnified with a 
vertical projection system. Optimal focus was reached at a magnification of 2.3 (the 
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scale bar of each MR-slice representing 100 mm of brain tissue measured at focus 
projection level 230 mm). A transparant counting grid with systematically ordered 
intersection points at 5 mm distance was randomly placed at focus level of the 
projected MR-slice. For determination of VCSF volumes the same transparant coun­
ting grid was placed directly and randomly on the photographic hardcopy of each 
MR-slice on an illuminator (figure 1). 
Volume estimations were based on Cavalieri's principle:30 the volume of any 
object may be estimated from randomized and parallel sections seperated by a known 
distance by summing up the areas of all cross sections of the object and multiplying 
this sum by the known distance. Images were randomized, since the first slice hitting 
SCL or VCSF fell randomly followed by systematic equidistant slices with a known 
distance equal to the slice thickness plus slice gap. Total area of all cross sections may 
be estimated by a stereological point counting method.74 A systematic array of grid 
intersection points is superimposed on each MR-slice. Giving random positioning of 
the test array on each MR-slice, the total number of grid intersection points Ρ hitting 
Figure 1. A randomly placed counting 
grid with systematically ordered inter­
section points at a 5-mm distance to 
determine ventricular CSF volume on a 
2500/20 MR section. The inner corner of 
the right upper quadrant of each inter­
section и the actual sampling point 
(arrow). 
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the object of interest affords an unbiased estimator of the total area. The grid 
intersection point was defined as the inner comer of the right upper quadrant of each 
intersection (figure 1). 
The total area of all SCL (ASCL) on all MR-slices can be estimated by the fol­
lowing equation: 
A j e (mm2) = Ρ χ a(p) (mm2) 
where Ρ is the total number of grid intersection points 
overlaying the SCL, a(p) is the areal equivalent of one 
grid point. 
a(p) (mm2) = 5 x 5 (mm2) / (magnification)2 
25 / (2.3)2 = 4.7259 (mm2) 
Total volume of SCL (VSCL) is then given by: 
VSCL (mm3) = AsCL (mm2) χ (slice thickness + slice gap) 
Ρ χ a(p) χ 4.4 (mm3) 
Ρ χ 4.7259 χ 4.4 (mm3) 
Ρ χ 20.79 (mm3) 
The same holds true for the estimation of VCSF volume: 
VVCSF (mm3) = AV C S F (mm2) χ 4.4 (mm) 
AV C S F (mm2) = Ρ χ a(p) (mm2) 
a(p) (mm2) = 5 x 5 / (magnification)2 (mm2) 
25 / (43.48/100)2 
132.25 (mm2) 
VVCSF (mm3) = Ρ χ 132.25 χ 4.4 (mm3) 
Ρ χ 581.9 (mm3) 
Statistics 
Statistical methods for validation of the stereological volume estimation method 
included: (a) the determination of the coefficient of error (CE) of the individual 
estimate of each SCL and VCSF volume74 compared to the determination of the 
coefficient of variation (CV) of the group mean; (b) the random intra- and inter-
observer error; (c) the systematic interobserver error. 
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The coefficient of error (CE) of the estimate of each individual SCL volume 
declines in direct proportion to the total number of MR planes and to the total 
number of grid intersection points P.74 Generally, a CE of less than 0.05 is obtained if 
the number of MR planes used is 10 or more and the number of grid intersection 
points is 50 or more.74 The mean number of MR planes in this study hitting SCL and 
through VCSF was always more than the minimum number of 10 and the mean num­
ber of grid intersection points was almost always more than 50. In quantification 
studies a CE of about 0.1 or less of the individual estimate seems appropiate with 
regard to precision, as the coefficient of variation of the group mean is always much 
higher mainly due to the large contribution of the biological variance to the coefficient 
of variation.72 The CE of the individual estimates was estimated using the quadratic 
approximation formula.74 
RESULTS 
Data on total number of grid intersection points Ρ of SCL and VCSF for both 
observers are shown in table 1. 
The range of coefficients of error of the individual estimates (CE) is 0.026-0.134 
for SCL and 0.011-0.068 for VCSF. The range of the coefficients of variation of the 
group mean (CV) is 0.873-0.894 for SCL and 0.699-0.717 for VCSF. 
The random intra- and interobserver errors are low for VCSF (respectively, 0.022 
and 0.043) and for SCL (0.043 and 0.116). The systematic interobserver error is 0.043 
for VCSF and 0.155 for SCL. 
DISCUSSION 
Until now, only semiquantitative rating scales4,15·49,79'147'184 were available for the 
assessment of signal hyperintensities on MR in which the severity of subcortical le­
sions (SCL) was expressed as a sum score of points awarded to subjective criteria like 
focal, multifocal, and confluent lesions,4,49,147 or punctate, nodular and patchy.15 
This study presents an accurate stereological method to quantify total volumes of 
subcortical lesions (SCL). This method has recently also been applied to estimate the 
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Table 1. Total number of hits (P) on subcortical lesions (SCL) and ventricular 
cerebrospinal fluid (VCSF) 
SCL VCSF 
observer la lb 2 la lb 2 
case 
SVP 
HTC 
SVP 
PD 
SVP 
SVP 
PD 
SVP 
PD 
HTC 
SVP 
SVP 
Ρ 
359 
1108 
589 
105 
71 
891 
97 
195 
472 
32 
509 
245 
Ρ 
346 
1153 
575 
117 
57 
883 
91 
213 
503 
39 
458 
236 
Ρ 
384 
1005 
427 
112 
91 
873 
66 
121 
489 
52 
495 
242 
Ρ 
325 
63 
181 
ИЗ 
53 
97 
152 
160 
30 
71 
43 
85 
Ρ 
325 
65 
181 
123 
53 
100 
157 
161 
31 
72 
46 
88 
Ρ 
341 
74 
180 
120 
58 
103 
155 
169 
29 
75 
46 
86 
la = observer 1 at time point 0; lb = observer 1 at time point 4 weeks; 2 = observer 2; Ρ = number of 
hits; SVP ж suspected vascular parkinsonism; PD = idiopathic Parkinson's disease; HTC = hypertensive 
control; SCL-volume = Ρ χ 20.79 (mm3) and VCSF-volume = Ρ χ 581.9 (mm3) (See Method, subheading 
stereological quantification method) 
volume of cerebral ventricles in hydrocephalic patients on brain CT-scans137 and to 
estimate the volume of several brain structures in Down syndrome on MR scans.176 
The sampling procedure of the volume data is largely unbiased as randomness combi­
ned with systematic sampling has been guaranteed: (a) the first MR-slice hits the SCL 
or VCSF randomly, followed by systematic slices with a known distance; (b) the set of 
systematic grid intersection points is placed randomly onto the (projected) MR-slice. 
However, the sampling procedure of the volume data is not fully unbiased: (a) each 
MR-slice has a certain thickness and as it is not infinitely thin, it will always bear the 
risk of partial volume effects; subjective assessment to the boundaries of the lesions 
and even the presence or absence of some subtle lesions cannot be ruled out comple­
tely; (b) each grid intersection point has a certain area and as it is not infinitely small, 
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there is a theoretical chance of overestimating the number of hits; to overcome this 
risk the definition of grid intersection point was made as the inner corner of the right 
upper quadrant of each intersection. 
The stereological method is sufficiently accurate, as the individual coefficients of 
error (CE) are relatively negligible to the coefficient of variation (CV) of the group 
mean, constituting only a minor contribution to the total variation of the group mean. 
The intraobserver systematic error was not determined, since it was very low and 
negligible. The method is reproducible as inter- and intraobserver random and 
systematic errors are low, especially when compared to the semiquantitative rating 
scales, that yielded Cohen's kappa coefficient values in the range of poor to fair inter-
and intraobserver agreements.147,184 The method described is fast, since point counting 
of SCL and VCSF is carried out within 15 and 5 minutes per patient, respectively. 
The method is cheap as expensive computerized image analysis systems are not 
necessary. Moreover, at any chosen grey-level such image analysis systems may 
overestimate results as they cannot differentiate pathological white matter hyper-
intensities from other high-signal foci of normal structures like Virchow-Robin spaces, 
deep gyri, and the rim around the tip of the frontal horn. Therefore, expert analysis 
remains necessary. 
The reproducibility (inter- and intraobserver random and systematic errors) of the 
stereological method is dependent on the brain structure under investigation, as 
reproducibility appears to be better for VCSF than for SCL. Apparently, the reprodu-
cibility of the chosen grey-level of the human eye for determining SCL is dependent 
on the observer, and on the moment of investigation. One possible solution to this 
problem is to minimize the MR-slice thickness in order to reduce partial volume 
effects and enable unambiguous identification of SCL, which is in fact a general 
requirement for volume quantification of any object at all.73 
In conclusion, the present study describes a simple stereologic method that can be 
applied on routine MR-scans in which the total volume of subcortical lesions is to be 
estimated. It is cheap, and preliminary results indicate that it is precise and reliable, 
and thus constitutes a new tool in volume measurement of subcortical lesions and 
potentially of any brain structure of interest. 
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INTRODUCTION 
Since Critchley (1929) popularized the concept of "arteriosclerotic parkinsonism",33 
many authors have challenged its existence.36,44·55'94,139 Computerized Tomography 
(CT) and Magnetic Resonance Imaging (MRI) have provided support for the concept 
of vascular parkinsonism.57,61,163,166 Atypical parkinsonism (without tremor or levodopa 
response) occurs with subcortical white or gray matter lesions (SCL),57,61,163,166 that 
correlate with arteriolosclerosis, demyelination with loss of axons, and chronic infarcts 
on postmortem studies18,39,104,121,171. Clinically, vascular parkinsonism, 'lower-half'163 or 
"lower-body parkinsonism",57 is dominated by "frontal gait disorder",133 with characteri-
stic shuffling, short steps, start and turn hesitation, variable base (narrow to wide), and 
moderate disequilibrium. 
The multiple etiologies of frontal gait disorder133 make diagnosis of vascular 
parkinsonism difficult. Moreover, infarction of the basal ganglia and deep white 
matter (or SCL on MRI and CT) occur in elderly people who do not have parkinso-
nism.4,44,52,55,79'88'172 Since some authors were unable to detect vascular lesions in 
patients meeting clinical criteria for idiopathic Parkinson's disease (PD),90 the 
existence of vascular parkinsonism was denied.44'139 Calne et al26 and Rowe and 
Kahn145 emphasized the necessity of obtaining proper controls. Because of the 
heterogenity for the risk factors for SCL among nondiseased elderly,4·52,88·172 care is 
needed in selecting a control group with full knowledge of the distribution of their 
individual risk factors. The best choice for controls are neurologically normal elderly 
persons with chronic hypertension, the main vascular risk factor for SCL.4,172 
The aim of our study was to investigate whether MRI can yield evidence for vas-
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cular lesions in suspected vascular parkinsonism. Therefore, we attemped to determi-
ne whether: (1) patients with clinically suspected vascular parkinsonism (SVP) have 
more SCL on MRI than patients meeting clinical criteria for idiopathic PD; (2) SVP 
patients have more SCL than hypertensive controls without parkinsonism or gait 
disorder; (3) SCL in SVP patients with an acute onset (SVPa) are located differently 
from SCL in SVP patients with an insidious onset (SVPi); and (4) the severity of 
parkinsonian symptoms in SVP patients is related to the volume and location of SCL· 
MATERIALS AND METHODS 
Patients and controls 
Fifteen PD patients (10 men, 5 women, age 72 ± 8 years, duration of disease 
7 ± 7 years), 15 SVP patients (11 men, 4 women, age 72 ± 4 years, duration of 
disease 3 ± 3 years) and 10 hypertensive controls were clinically examined and with 
MRI. All PD and SVP patients were selected consecutively from the departments of 
Neurology and Geriatrics in our hospital, blind to the results of any possible previous 
MRI, CT or history of vascular risk factors. PD was diagnosed in accordance with 
accepted clinical criteria.90 SVP was diagnosed in patients 60 years or older with 
parkinsonism (hypokinesia and rigidity), dominated by frontal gait disorder,57'133,159,163 
and the following exclusion criteria: resting tremor, neuroleptic therapy, brain trauma, 
supranuclear gaze palsy, retrocollis, disproportionate antecollis, cerebellar signs at 
onset, fixed dystonic posture of the arm, action or stimulus-sensitive myoclonus of the 
arm, alien hand, polyneuropathy, respiratory stridor, and orthostatic hypotension 
(> 30 mmHg).90,94,142 Four of the SVP patients had an acute onset (SVPa), whereas in 
the remainder the onset was insidious (SVPi). One SVPa patient showed a good 
response to levodopa and carbidopa for three years, whereas in the others the 
response to levodopa and carbidopa (up to Sinemet 275, 3 times daily) was absent or 
minimal. Some SVP patients had dysarthria, pyramidal signs or signs of frontal lobe 
release, such as grasp reflexes or pseudobulbar reflexes. Four SVP patients had a 
history of hypertension, 4 of diabetes mellitus, and 9 had a history of a transient 
ischemic attack (TIA) or reversible ischemic neurological deficit (RIND). Patients 
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with other neurological diseases or with cognitive impairment (Mini Mental State 
Examination <23)58 were excluded. 
The 10 hypertensive patients (6 men, 4 women, age 70 ± 2 years, duration of 
hypertension 18 ± 13 years) were selected consecutively from the outpatient depart­
ment of Internal Medicine. They had neither parkinsonism nor gait disorder and met 
the exclusion criteria as described above. In all patients, informed consent was 
obtained prior to the examination in accordance with institutional guidelines. 
Methods 
All patients and controls were examined by one investigator (J.C.M.Z.), who 
assessed severity of arm and leg rigidity in accordance with the Unified Parkinson's 
Disease Rating Scale,48 severity of hypokinesia using a pegboard test as described in a 
previous study,89 and gait velocity during free speed walking by measuring the time 
needed to cover a distance of 10 meters. Blood pressure was measured with a legally 
stamped sphygmomanometer (Erka-meter 300) after 5 minutes of supine rest. At the 
time of clinical examination, no patient had taken levodopa during the preceding 12 
hours. 
MRI examination was performed with a 1.5 tesla Magnetom (Siemens, Erlangen, 
Germany) and a spin-echo sequence SE PDW-T2W (TE 20 and 80 msec; TR 2,500 
msec). Images through the whole brain were acquired in the transversal plane, parallel 
to the intercommissural line, with a slice thickness of 4 mm and a slice gap of 0.4 mm. 
Spatial resolution was 0.95 mm, corresponding to a 256 χ 256 matrix. All MRI scans 
had an identical field of view. 
Two investigators (J.C.M.Z., O.J.M.V.), blind to the identity of the imaged 
patients, interpreted the MRI scans for the volume and location of SCL as evident 
from areas with increased signal intensity on both short and long TE (echo time) 
images. Perivascular dilatations (isointense relative to CSF on short TE images) and 
hyperintense rims around the tip of the frontal horn were not scored, because they 
are of non-ischemic origin.17,52 
The SCL volume was determined by a stereological estimation using a point 
counting method (Gundersen and Jensen72) and the Cavalieri theorem of systematic 
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sampling (Cavalieri30). This method uses systematic sampling of parallel sections with 
a known, fixed interval (in this study 4.4 mm, i.e. MRI slice thickness plus slice gap) 
and estimation of area using counting grids. It was applied to estimate the volume of 
cerebral ventricles in hydrocephalic patients on brain CT-scans and to estimate the 
volume of several brain structures in Down's syndrome on MR images.137,176 We 
estimated the total area of all SCL (Aj^) on all MRI slices by superimposing a syste­
matic array of test points on each slice. Giving random positioning of the test агтау on 
each slice, the total number of test points ΣΡ that hit SCL affords an unbiased esti­
mator of the total area of SCL (AsCL). The exact relationship is: 
ASCL = ΣΡ χ a(p) (mm2) 
where a(p) is the areal equivalent of one test point. Total volume of SCL (VSCL) is 
given by: 
VSCL (mm3) = ASCL ( m m 2 ) x 4 · 4 ( m m ) · 
The coefficient of error (CE) of the estimate of each individual SCL volume declines 
in direct proportion to the total number of MRI slices and to the total number of test 
points.72 In our study, a CE of less than 5% was obtained, because the number of 
MRI slices hitting SCL was 10 or more and the number of test points was 50 or 
more.
173
 The systematic and random errors of the VSCL-estimates of the two investiga­
tors (inter-observer variability) and also that of one investigator at two points, a four-
week interval, (intra-observer variability) are described elsewhere.173 They were all 
approximately 10%. This indicates a high reproducibility of the method, especially 
when compared to the recently developed semiquantitative rating scales in which the 
severity of SCL is expressed as a sum score of points awarded to subjective criteria, 
such as focal, multifocal, and confluent lesions,4'79,147 or punctate, nodular and 
patchy,15 yielding Cohen's kappa coefficient values of inter- and intra-observer agree­
ments ranging from 0.34 to 0.73.147 The SCL volume was finally expressed as a 
percentage of total brain tissue volume: (VSCL/ VBRAIN ·π5 5 υ Ε) χ 100%, whereas VBRAIN 
TISSUE w a s similarly obtained as VSCL. 
The SCL were also scored in respect to location of: (1) territories of the three 
main cerebral arteries (anterior, middle and posterior cerebral arteries); (2) territories 
of the three watershed areas (between the anterior/middle, the middle/posterior cere-
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bral arteries and the deep/superficial medial arteries); and (3) the subcortical gray 
nuclei (putamen, caudate nucleus, globus pallidus, thalamus and substantia nigra). 
Statistics 
To compare the SCL volume in the two SVP groups, PD patients, and hypertensi­
ve controls, the Mann-Whitney test with Bonferoni adjustment for multiple compari­
sons was used. To determine whether SVPa and SVPi patients could also be differen­
tiated from each other by the presence of SCL in the gray nuclei, Fisher's exact test 
(two-tailed) was used. Finally, the severity of the parkinsonian symptoms of the SVP 
patients and their relation to the volume and location of SCL were examined with the 
Spearman's rank correlation. For the unilateral tests (arm and leg rigidity, pegboard), 
the more severely affected side of the body was correlated with the total SCL volume. 
In all test procedures, ρ < 0.05 was considered significant. 
RESULTS 
SVP patients did not differ significantly from PD patients or hypertensive controls 
in age, systolic blood pressure or diastolic blood pressure (table 1). The SVP group 
scored significantly lower than PD patients in rigidity in the upper and lower extre­
mities (table 1). Pegboard score and walking velocity were not appreciably different 
between the two patient groups. SVP patients had a significantly higher pegboard 
score and a significantly lower walking velocity than controls (table 1). The 4 SVPa 
patients were not crucially different from the 11 SVPi patients in age, systolic blood 
pressure, diastolic blood pressure, pegboard test, arm and leg rigidity or walking 
velocity (data not shown). Current blood pressure did not differ significantly by 
oneway ANOVA between the SVPi group and the controls (152 ± 16/ 88 ± 11 vs 
166 ± 21/ 91 ± 8 mm Hg). 
Figure 1 shows MRI studies of an SVPa and an SVPi patient. SVPi patients had 
markedly more SCL than did patients with PD (p<0.01; Mann-Whitney test) or 
hypertension (p<0.05)(figure 2). SVPa patients had significantly more SCL than did 
PD patients (p<0.05), but not more than hypertensive controls (figure 2). The SCL 
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Table 1. Patient characteristics 
age (years) 
systolic BP 
(mm Hg) 
diastolic BP 
(mm Hg) 
pegboard test 
(sec) 
arm rigidity 
(UPDRS) 
leg rigidity 
(UPDRS) 
velocity of walking 
(cm/sec) 
SVP (η = 15) 
Mean ± SD 
72 ± 4 
154 ± 18 
91 ± 11 
10.8 ± 6.1 
1.0 ± 0.8 
1.2 ± 0.9 
60 ± 26 
PD (n = 15) 
Mean ± SD 
72 + 8 
145 ± 15 
89 ± 15 
10.6 ± 6.1 
2.0 ± 0.6 ** 
1.9 ± 0.6 * 
59 ± 2 9 
Controls (n = 10) 
Mean ± SD 
70 ± 2 
166 ± 2 1 
91 ± 8 
5.7 ± 0.8 · · 
-
-
117 ± 24 ** 
PD = Parkinson's disease; SVP = suspected of vascular parkinsonism; BP = blood pressure. 
* : p< 0.05; ** := p< 0.01 (t-test): PD and controls compared to SVP group. 
Figure 1. Spin-echo proton density-weighted MRI studies showing subcorneal lesions in a patient 
with acute onset of suspected vascular parkinsonism (A) and a patient with insidious onset of 
suspected vascular parkinsonism (B). 
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volume was not significantly different between the two SVP groups. A cutoff point for 
SCL volume of 0.6% of brain tissue volume resulted in the best discrimination 
between PD and SVP groups (figure 2). Three hypertensive controls had an SCL 
volume >0.6% (table 2). 
All four SVPa patients had SCL in the gray nuclei, but only two of the 11 SVPi 
patients did (p=0.02; Fisher's exact test, two tailed)(table 2). None of the PD patients 
or controls had gray nuclei SCL (table 2). SCL in the gray nuclei were located in the 
putamen or thalamus alone or in one of those two nuclei along with SCL in the 
globus pallidus or caudate nucleus. 
The severity of clinical symptoms (gait velocity, arm and leg rigidity, pegboard 
score) was significantly correlated with neither the total SCL volume in the SVP pa­
tients nor the location of the SCL as seen from the subscores of the blood supplying 
territories of the three main cerebral arteries, the three watershed areas between 
these three arteries, and the subcortical gray nuclei (Spearman's rank correlation). 
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Table 2. Cross tabulation of clinical and lesion groups 
PD SVPi SVPa Controls 
n = 15 n = l l n = 4 n = 10 
SCL-/SGN- 14 1 0 7 
SCL+/SGN- 1 8 0 3 
SCL+/SGN+ 0 2 4 0 
PD = Parkinson's disease; SVPi = suspected of vascular parkinsonism, insidious onset; 
SVPa = suspected of vascular parkinsonism, acute onset. 
SCL- = total SCL volume <0.6%; SCL+ = total SCL volume iO.6%; SGN+ = subcortical 
gray nuclei lesions present; SGN- = subcortical gray nuclei lesions not present. 
The SCL were diffusely distributed, mainly in the three watershed areas, with only a 
small variation between the four patient groups. Of the total SCL load, 0 to 3% was 
located in the territories of the three main cerebral arteries; 40 to 50% in the 
watershed area of the anterior/middle cerebral arteries; 15 to 20% in the watershed 
area of the deep/superficial middle cerebral arteries; 30 to 40% in the watershed area 
of the middle/posterior cerebral arteries; and 0 to 14% in the subcortical gray nuclei. 
DISCUSSION 
We suspected that 15 patients had vascular parkinsonism because they demonstra­
ted lower-half parkinsonism163 with frontal gait disorder,133 no resting tre-
mor
3i33
r
57,6i,i39,i63,i6«
 a n d т і п і т а ] o r abSent levodopa response.31·57,139·166 As described 
previously, arm and leg rigidity in SVP patients was less severe than in PD pa­
tients.57,163 Gait velocity and hypokinesia, examined with a pegboard test, were as 
severe in SVP as in PD patients. FitzGerald and Jankovic57 found hand dexterity less 
affected in SVP than in PD, but they assessed hand dexterity by finger tapping, where­
as we used a pegboard test. Four SVP patients had an acute onset, but they were not 
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further distinguishable on clinical grounds from the other 11 SVP patients, who had 
an insidious onset. 
Our MRI study supports the concept of vascular parkinsonism. SVP patients had 
a significantly higher SCL volume than PD patients, indicating that SVP patients are 
distinguishable from PD patients not only clinically but also radiologically. The cutoff 
point of SCL volume for distinguishing SVP from PD patients appeared to be 0.6% 
lesioned volume of brain tissue. This cutoff point yielded the best discrimination 
between the two groups. Only one patient clinically diagnosed as having idiopathic PD 
showed a higher SCL volume (2.36%), while only one patient with SVP showed a 
lower volume (0.33%). However, although the criteria we used for determining the 
presence of vascular or idiopathic parkinsonism agree with accepted clinical standards, 
the definite gold standard, i.e., post-mortem examination,90 was not available. 
SVP patients also had significantly more SCL than a group of neurologically 
normal hypertensive elderly. This suggests a causal relationship between SCL and 
parkinsonism in our patients with SVP. The difference in SCL volume between the 
SVP and control patients was influenced neither by hypertension history nor by 
current blood pressure. Only four of 15 SVP patients had a history of hypertension. 
Neither the current systolic nor the diastolic blood pressure differed between the two 
groups. Three of ten hypertensive controls had an SCL volume of >0.6% of brain 
tissue, indicating an overlap between the SVP patients and the controls. These results 
parallel the findings of Fazekas52 and Horikoshi et al,88 who reported frequencies of 
10 to 30% of partially or widely confluent lesions in asymptomatic elderly having 
vascular risk factors. Older persons without vascular risk factors may not serve as a 
control group, because of the probability of their having a lower SCL volume than our 
SVP patients who were not selected because of absence of vascular risk factors. PD 
patients are also not an optimal control group. They might have fewer vascular risk 
factors than usual145 healthy individuals;66,158 PD patients have a lower frequency of 
tobacco use,66,158 a known risk factor for atherosclerotic vascular disease.87 
In both SVP groups, SCL were diffusely located mainly in the watershed areas, in 
agreement with repors by others.31,57,163 Furthermore, all four SVPa patients had SCL 
in the gray nuclei, also in agreement with other reports.31'61,166 In the four SVPa pa-
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tients, subcortical gray nuclei lesions were located in the putamen or thalamus alone 
or in one of these nuclei along with the globus pallidus or caudate nucleus. There 
were no SCL in the substantia nigra. The differentiation of vascular parkinsonism into 
two types on the basis of their stage of onset and the location of SCL, has not been 
examined previously. There probably are more types of vascular parkinsonism in 
which other locations are involved, such as types resembling progressive supranuclear 
palsy.42·178 
In patients with dementia63,93,104 or in whom mental impairment was not exclu-
ded,15* the presence of gait impairment was associated with SCL· We did not find a 
significant correlation between the severity of symptoms in the SVP patients and the 
volume or location of SCL· probably because of the rather low SCL volume in our 
slightly affected SVP patients. 
Thompson and Marsden,163 and Fitzgerald and Jankovic57 suggested that the par-
kinsonism in patients showing deep white matter lesions on MRI or CT might be due 
to subcortical ischemia.57163 However, in a previous study with proton magnetic reso-
nance spectroscopy in SVP patients, we could not detect metabolic signs of ischemia 
(increased lactate) in deep white matter or in the striatum.186 Meguro et al123 reported 
impaired circulation in brains with severe SCL·, although oxygen metabolism was not 
measurably affected. Vascular parkinsonism is probably due to multiple acute 
ischemic micro-infarcts resulting in neuronal cell loss, while, later on, lactate normali-
zes by diffusion and active transport and mechanisms appear that compensate for the 
decreased oxygen supply resulting from decreased circulation.123 The location of SCL 
mainly in the watershed areas indeed indicates their ischemic nature. 
In conclusion, we showed that SVP patients had more SCL than patients with PD 
and hypertension. This suggests a causal relationship between SCL and parkinsonism 
in our patients with SVP. We observed two types of vascular parkinsonism: one had 
an insidious onset and its vascular lesions diffusely located in the watershed areas; the 
other had an acute onset and lesions located in the subcortical gray nuclei (striatum, 
globus pallidus, thalamus). To prove the accuracy of clinical symptoms and SCL in the 
diagnosis of vascular parkinsonism, post-mortem examination studies of SVP patients 
are necessary. 
CHAPTER 5 
Quantitative gait analysis in patients with 
Vascular Parkinsonism 
Zijlmans JCM, Poels PJE, Duysens J, van der Straaten J, Thien Th, van 't Hof MA, 
Thijssen HOM, Horstink MWIM 
Movement Disorders, accepted for publication 
INTRODUCTION 
Since Critchley (1929) drew the attention to the concept of "arteriosclerotic 
parkinsonism"33 many authors have challenged its existence.36,44,55,94'139 Recently we 
showed that patients clinically suspected of VP indeed had more subcortical lesions 
(SCL) on MRI than patients with idiopathic Parkinson's disease (PD) and controls.187 
However, there is still debate on the typical clinical syndrome. Thompson and 
Marsden163 have suggested, in accordance with Critchley,33 that patients with vascular 
parkinsonism have short shuffling steps, upright posture and lack excessive flexion of 
the legs as seen in idiopathic Parkinson's disease (PD). However, in contrast to 
Critchley33 they have also suggested an increased step width and a loss of the normal 
synergy between associated upper limb and truncal movements.163 Vascular parkinso-
nism is also called 'lower-half'163 or "lower-body parkinsonism",57 because difficulty in 
walking is the most prominent initial symptom. Nutt et al133 prefer to use the term 
"frontal gait disorder" for these patients which, according to them, is characterized by 
shuffling, short steps, start and turn hesitation, variable base (narrow to wide) and 
moderate disequilibrium. 
The aim of the present study is to investigate whether quantitative gait analysis 
can differentiate between the gait pattern of VP and the gait pattern of PD. To 
determine which variables of gait are abnormal in VP, the gait of the VP group was 
also compared to neurologically non-diseased same-aged controls. Furthermore, the 
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relationship in VP between the severity of gait impairment and SCL load on MRI was 
investigated. 
METHODS 
Patients 
Twelve VP patients (9 men, 3 women), 12 PD patients (7 men, 5 women) and 10 
neurologically non-diseased controls (6 men, 4 women) were examined by quantitative 
gait analysis. PD was diagnosed in accordance with accepted clinical criteria.90 VP was 
diagnosed in patients 60 years or older with parkinsonism (hypokinesia and rigidity), 
dominated by frontal gait disorder,57,133'159,163 and the following exclusion criteria: 
resting tremor, neuroleptic therapy, brain trauma, supranuclear gaze palsy, retrocollis, 
disproportionate antecollis, cerebellar signs at onset, fixed dystonic posture of the arm, 
action or stimulus-sensitive myoclonus of the arm, alien hand, polyneuropathy, 
respiratory stridor, and orthostatic hypotension (> 30 mmHg).90,94'142 One VP patient 
had a good response to levodopa and carbidopa for three years, whereas in the 11 
others the response to levodopa and carbidopa (up to Sinemet 275 mg, 3 times daily) 
proved to be absent or minimal. Patients with cognitive impairment (Mini Mental 
State Examination score <23),58 and other neurological diseases, except Transient 
Ischemic Attack (TIA) or Reversible Ischemic Neurological Deficit (RIND) were 
excluded. Special attention was paid to the exclusion of patients with disorders that 
give "cautious gait",133 like musculoskeletal, peripheral nervous motory and sensory 
lesions. MRI did not reveal a high SCL load in the PD patients, whereas all VP 
patients showed extended SCL as described in a previous study.187 To reduce the 
effect of medication at the time of gait analysis, regular levodopa and dopa-agonist 
therapy had been discontinued for the preceding 12 hours. The control group 
consisted of the ten neurologically non-diseased patients, who participated in a 
previous study.187 In all cases informed consent was obtained prior to the examination 
in accordance with institutional guidelines. All patients and controls were examined by 
one investigator (J.C.M.Z.) for severity of hypokinesia using a pegboard test as 
described in a former study,89 as well as by quantitative gait analysis. 
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Procedures of gait analysis 
Gait analysis consisted of kinematic, spatial and temporal measurements during free 
chosen speed walking. Kinematic variables are maximum and minimum angular 
excursions of the shoulder, elbow, hip, knee and trunk in the sagittal plane; amplitu-
des of total excursions in these angles; and phase shifts of the moments in the gait 
cycle when maximum shoulder, minimum hip, and maximum knee flexion usually are 
present. Spatial variables are stride length and step width. Temporal variables are gait 
velocity and stride time. 
The kinematic variables were obtained by digitizing videotapes of walking with a 
VMCMAS-system (Nijmegen, the Netherlands) as has been previously described;169 in 
a manner similar to Winter.179 Patients were prepared with skin markers on 8 specific 
anatomical landmarks: 1) earlobe, 2) shoulder acromioclavicular process, 3) elbow -
lateral epicondyle of humerus, 4) wrist - ulnar head, 5) hip - greater trochanter, 6) 
knee - lateral femoral epicondyle, 7) knee - fibular head and 8) ankle - lateral malleo-
lus. The subjects traversed a 10-m walkway, 6 meters in front of a videocamera. The 
recordings were displayed on a video recorder connected to the overlay board of a 
computer. In the computer the video signal was merged with a TAIGA (Twente Ad-
vanced Interactive Graphic Authoring, University of Twente, the Netherlands) pro-
gram, and the coordinates of the skin markers on the body segments were digitized 
manually. The lines between the markers and the relative angles could be calculated 
from these coordinates. Frames were digitized at 0.04 second intervals, and the time 
axis was plotted as percent of gait cycle, which extended from one foot contact (0% of 
gait cycle) to the next ipsilateral foot-contact (100% of gait cycle) (figure 1). Registra-
tion was limited to the patients's most affected side. Maximum and minimum excur-
sions of the above mentioned angles were calculated. Also, the phase shifts of mo-
ments in gait cycle when maximum shoulder angle (50% of gait cycle), minimum hip 
angle (50%) and maximum knee angle (75%) usually are present179 were computed. 
These three moments are the most characteristic coordination measurements of the 
extremities during walking.130,179 The phase shifts were expressed as an absolute per-
centage of gait cycle, disregarding a positive or a negative value. The averages of 
three gait cycles were calculated for all kinematic variables. 
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Figure 1. Spatial and temporal variables in gait cycle. 
Spatial variables (stride length and step width) were obtained by making footprints 
with magnesium powder while wearing standard shoes. Stride length was denned as 
the linear distance between two consecutive ipsilateral foot contacts on the walking 
surface, in the line of walking progression (figure 1). Step width was defined as the 
perpendicular distance between consecutive midheel placement locations, relative to 
the line of walking progression (figure 1). The average of both stride length and step 
width during six gait cycles was calculated. 
Temporal variables (stride time, gait velocity) were obtained with foot-swiches 
located in standard shoes under the areas of the heel and metatarsal heads, similar to 
the method used by Dietz et al.40 Stride time (the time needed to complete a gait 
cycle) was defined as the time elapsed between consecutive ipsilateral foot contacts on 
the walking surface (figure 1). Gait velocity was calculated by dividing stride length by 
stride time. The averages of six gait cycles were calculated for all temporal variables. 
Statistical analyses 
The main objective of our study was to determine if any gait variable was significantly 
different between VP patients and PD patients, and for this purpose the t-test was 
used. To investigate if the results were significantly influenced by patient's age, sex, 
body length and weight, analysis of variance was performed. In addition, to determine 
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whether VP patients were significantly different from the control group concerning the 
gait variables the t-test was used, and again analysis of variance was performed to 
investigate if the results disclosed by the t-test were significantly influenced by 
patient's age, sex, body length and weight. Finally, the severity of the gait impairment 
of the VP patients and its relation to the SCL volume, as was obtained in a previous 
study,187 was examined with the Spearman's rank correlation. 
RESULTS 
VP patients did not differ significantly from PD patients or controls regarding age, 
body length and weight (table 1). The disease duration was also not significantly diffe-
Table 1. Mean and standard deviation for characteristics of VP patients compared to 
PD patients and controls 
age (years) 
disease duration 
(years) 
body length (m) 
body weight (kg) 
pegboard test 
(sec) 
VP 
n = 12 
71 ± 4 
4 ± 3 
1.73 ± 0.12 
71 ± 4 
10.8 ± 6.1 
PD 
η = 12 
72 ± 8 NS 
5 ± 3 N S 
1.69 ± 0.10 NS 
72 ± 14 NS 
10.6 ± 6.1 NS 
Controls 
η = 10 
70 ± 2 NS 
-
1.73 ± 0.11 NS 
77 ± 15 NS 
5.7 ± 0.8 ** 
PD = Parkinson's disease; VP = vascular parkinsonism, 
t-test; NS = not significant, **p< 0.01. 
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Table 2. Mean and standard deviation (in degrees) for maximum, minimum and total 
angular excursions of the gait of VP patients compared to PD patients and controls 
shoulder angle: 
maximum 
minimum 
total 
elbow angle: 
maximum 
minimum 
total 
hip angle: 
maximum 
minimum 
total 
knee angle: 
maximum 
minimum 
total 
truncal angle: 
maximum 
minimum 
total 
VP 
n = 12 
0 ± 10 
-19 ± 9 
19 ± 8 
34 ± 9 
22 ± 8 
12 ± 5 
26 ± 6 
-4± 9 
30 ± 6 
55 ± 8 
9 ± 5 
46 ± 8 
13 ± 5 
8 ± 5 
5 ± 1 
PD 
η = 
-12 ± 
-22 ± 
10 ± 
43 ± 
32 ± 
11 ± 
33 ± 
6 ± 
27 ± 
60± 
15 ± 
45 ± 
17 ± 
13 ± 
4 ± 
> 
12 
12* 
IONS 
4 ** 
12 (*) 
12* 
4 NS 
12 (*) 
17 (*) 
7 NS 
6 η 
ЮС) 
IONS 
9 NS 
IONS 
INS 
Controls 
η = 10 
7 ± 9 NS 
-18 ± 5 NS 
25 ± 11 NS 
33 ± 11 NS 
18 ± 5 NS 
15 ± 12 NS 
29 ± 5 NS 
-10 ± 5 (*) 
39 ± 3 ** 
66 ± 3** 
4 ± 4 ** 
62 ± 4 ** 
9 ± 4 * 
3 ± 4 * 
6 ± INS 
PD = Parkinson's disease; VP = vascular parkinsonism. 
Total angular excursion = maximum - minimum angle, 
t-test; NS = not significant, (*)p<0.10, *p<0.05, **p<0.01. 
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Vascular 
Parkinsonism 
Vascular 
Parkinsonism 
Figure 2. Sagittal shoulder rotation was 
measured from the angle between the me-
chanical axis of the upper arm and a vertical 
reference (a vertical line through acromion). 
Positive values indicate that the upper arm 
was flexed in front of the line of reference; 
negative values indicate that the upper arm 
was extended behind the line of reference. See 
text for specific anatomical landmarks of skin 
markers. 
Figure 3. Sagittal maximum and minimum 
(virtual, Le. imaginary) elbow angles were 
measured from the angle between an extended 
axis of the upper arm and the mechanical 
axis of the forearm. See text for specific 
anatomical landmarks of skin markers. 
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rent between the two patient groups (table 1). Both VP and PD patients had a signifi­
cantly higher pegboard score than the controls (table 1). The pegboard score was not 
significantly different between the two patient groups. 
VP patients showed significantly greater amplitudes of total shoulder excursion, 
larger maximum shoulder angles and smaller minimum elbow angles than PD patients 
(table 2, figures 2 and 3). There was also a tendency for VP patients to have a smaller 
maximum elbow angle than PD patients. Furthermore, VP patients had a significantly 
smaller phase shift of the moment of gait cycle when maximum shoulder angle usually 
is present than PD patients (table 3). VP patients were not significantly different from 
the control group in regards to the amplitudes of total shoulder and elbow excursions, 
maximum and minimum shoulder and elbow angles or the phase shift of the moment 
of gait cycle when maximum shoulder angle usually is present (tables 2 and 3, figures 
2 and 3). 
Table 3. Mean and standard deviation for gait coordination variables in VP patients 
compared to PD patients and controls 
p.s. maximum 
shoulder angle (%) 
p.s. minimum 
hip angle (%) 
p.s. maximum 
knee angle (%) 
VP 
n = 12 
5 ± 2 
7 ± 3 
5 ± 2 
PD 
η = 12 
13 ± 12 * 
8 ± 4 N S 
4 ± 3 N S 
Controls 
η = 10 
3 ± I N S 
5 ± 2NS 
4 ± I N S 
PD = Parkinson's disease; VP = vascular parkinsonism. 
p.s. = phase shift of moment in gait cycle (0 - 100%), see text for explanation. 
t-test; NS = not significant, *p<0.05. 
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VP patients showed significantly smaller amplitudes of total hip and knee excur-
sion, and a smaller maximum and a larger minimum knee angle than the controls 
(table 2, figures 4 and 5). There also was a tendency for VP patients to have a larger 
Vascular 
Parkinsonism 
Parkinson's 
disease 
Vascular 
Parkinsonism 
Figure 4. Sagittal hip rotation was measured 
from the angle between an extended 
axis of the trunk and the mechanical axis of 
the upper leg. Positive values indicate that the 
upper leg was flexed in front of the line of 
reference; negative values indicate that the 
upper leg was extended behind this line. See 
text f or specific anatomical landmarks 
of skin markers. 
Figure 5. Sagittal maximum and minimum 
(virtual, Le. imaginary) knee angles were 
measured from the angle between an extended 
axis of the upper leg and the mechanical axis 
of the lower ¡eg. See text for specific 
anatomical landmarks of skin markers. 
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minimum hip angle than the controls. Furthermore, VP patients did not have signifi-
cantly different amplitudes of total hip and knee excursion than PD patients. There 
was a tendency for VP patients to have a smaller maximum and minimum hip angle 
and a smaller maximum and minimum knee angle than PD patients (table 2, figures 4 
and 5). VP patients did not have significantly different phase shifts of the moments of 
time in gait cycle when minimum hip and maximum knee angle usually are present 
than PD. patients and the controls (table 3). 
VP patients did not have a significantly different amplitude of total truncal 
excursion than PD patients and controls (table 2, figure 6). They also did not have a 
Controls Vascular Parkinson's 
Parkinsonism disease 
Figure 6. Sagittal truncal rotation was measured from the angle between the line that connected 
the earlobe with the major trochanter and a vertical reference (a vertical line through major 
trochanter). See text for specific anatomical landmarks of skin markers. 
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significantly different maximum and minimum truncal angle than PD patients. In 
contrast, VP patients did have significantly larger maximum and minimum truncal 
angles than the controls. 
Both VP and PD patient groups showed shorter stride length, broader step width, 
slower gait velocity and longer stride time than the controls (table 4). None of the 
examined spatial and temporal variables were significantly different between VP and 
PD patients (table 4). 
The results from kinemetic, spatial and temporal measurements remained 
significant after correction for patient's age, sex, body length and weight (all ρ > 0.05, 
analysis of variance). 
There was no significant correlation between gait velocity and total SCL score in 
the 12 VP patients (p>0.05; Spearman's rank correlation). 
Table 4. Mean and standard deviation for stride dimensions and temporal compo­
nents of the gait of VP patients compared to PD patients and controls 
stride length (m) 
step width (cm) 
gait velocity (m/s) 
stride time (s) 
VP 
η = 12 
0.83 ± 0.22 
12 ± 6 
0.67 ± 0.21 
1.3 ± 0.2 
PD 
η = 12 
0.86 ± 0.28 NS 
9 ± 4 N S 
0.66 ± 0.25 NS 
1.3 ± 0.2 NS 
Controls 
η = 10 
1.29 ± 0.19 ·« 
5 ± 3 * * 
1.17 ± 0.24 ** 
1.1 ± 0.1 * 
PD = Parkinson's disease; VP = vascular parkinsonism, 
t-test; NS = not significant, *p<0.05, **p<0.01. 
DISCUSSION 
The aim of the present study was to investigate whether quantitative gait analysis 
64 Chapter 5 
can differentiate the gait pattern of VP from the gait pattern of PD. 
The data of our PD patients are similar to those of other studies concerning 
kinematic (angular excursions of the shoulder, elbow, hip and knee joints),110,130 
spatial (stride length, step width)110,129,lîî and temporal variables (gait velocity, stride 
time).11,110,129'155 For non-diseased elderly there is a considerable overlap in temporal 
and spatial data due to different investigation settings.40'47,62,113'129'130 The control data 
in this study are comparable with those of most previous studies concerning kinema-
tic,40,47,129,130 spatial62,113,129 and temporal variables.62,113,129 Spatial, temporal and 
kinematic data of patients with vascular parkinsonism are not yet published. 
VP patients, PD patients and controls did not differ in age, body length and 
weight. There were no differences between the two patient groups regarding disease 
duration and severity which was assessed by the following facets of hypokinesia. Gait 
velocity, stride length and step frequency (measured as stride time) were equally 
reduced in the two patient groups. Upper limb hypokinesia, as examined by a 
pegboard test, was also equally present in both patient groups. Furthermore, VP as 
well as PD patients showed a broader step width than the controls. 
VP patients, however, had a different gait pattern than PD patients, especially as 
far as the upper extremity is concerned. VP patients showed more arm swing (greater 
amplitude of total shoulder excursion), more anteflexion of the shoulder on the 
forward arc of the arm swing (larger maximum shoulder angle), and the elbows were 
less flexed throughout the gait cycle (smaller maximum and minimum elbow angles) 
than PD patients. Furthermore, VP patients showed a better coordination of shoulder 
movements (smaller phase shift of the moment of gait cycle when maximum shoulder 
angle usually is present) than PD patients. The excursions and coordination of arm 
swing in the VP patients were not different from the control group. 
In VP patients most of the gait components of the leg were similarly affected as in 
PD patients. Compared to controls, both VP and PD patients showed reduced leg 
movements (smaller amplitudes of total hip and knee excursion), reduced hip 
extension at the time of contralateral heel-strike (larger minimum hip angle), reduced 
knee flexion during the swing phase (smaller maximum knee angle) and reduced knee 
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extension at the beginning of the gait cycle when the limb is projected forward for the 
initial foot contact (larger minimum knee angle). VP patients, however, had less hip 
and knee flexion throughout the gait cycle (maximum and minimum hip and knee 
angles) than PD patients. Both VP and PD patients showed preserved coordination of 
hip and knee movements. In comparison to the controls, neither patient group had 
more phase shift of the moments of gait cycle when minimum hip angle and maximum 
knee angle usually are present. Truncal mobility (amplitude of total excursion of the 
trunk) in VP patients was not reduced compared to the controls. Like PD patients, 
VP patients had more truncal flexion throughout the gait cycle (larger maximum and 
minimum truncal angle) than the controls. In VP patients truncal flexion was less 
pronounced, although not significant, than in PD patients. 
Our results are generally in accordance with those of Critchley33 and Thompson 
and Marsden,163 who described relatively preserved arm swing,163 preserved coordina-
tion of shoulder movements,33 no excessive flexion of hip and knee as in PD33,163 and 
wide base163 in their patients with vascular parkinsonism. In contrast to our results, 
Critchley33 and Thompson and Marsden163 described upright posture,33,163 loss of 
truncal mobility,33,163 straight legs163 and no widening of step width.33 These differen-
ces can be caused by different selection criteria of subjects. Thompson and Mars-
den163 probably compared their VP patients with PD patients who had a more advan-
ced stage of disease than the PD patients from our study. They made no comparison 
with controls, and therefore did not notice a slightly reduced extension of the knee in 
VP patients at the beginning of the gait cycle when the limb is projected forward for 
the initial foot contact, and of the trunk throughout the gait cycle compared to non-
diseased elderly. Furthermore, our VP patients probably were more severely disor-
dered than the patients in their study. Critchley33 and Thompson and Marsden163 did 
report a flexed posture of the trunk and limbs in their most severely affected VP pa-
tients. 
In patients with dementia63,93 or in whom mental impairment was not excluded156 
the presence of gait impairment was associated with SCL. We did not find a correla-
tion between the severity of symptoms in the VP patients and the SCL volume, 
probably because of the rather low SCL volume in our slightly affected VP patients. 
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In conclusion, this study shows that quantitative gait analysis can differentiate the 
gait pattern of VP patients from the gait pattern of PD patients in whom gait velocity 
was equally reduced. VP patients have a more preserved arm swing, more (i.e. 
normal) anteflexion of the shoulder on the forward arc of the arm swing, less (i.e. 
normal) flexed elbows throughout the gait cycle and a better preserved (i.e. normal) 
coordination of shoulder movements than PD patients. Although VP patients show 
less flexion dystonic posture of hip, knee and trunk throughout the gait cycle than PD 
patients, leg and truncal movements in VP patients are less well preserved than arm 
movements. 
CHAPTER б 
EEG findings in patients with vascular parkinsonism 
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INTRODUCTION 
Since Critchley (1929)33 drew the attention to the concept of "arteriosclerotic 
parkinsonism" many authors have challenged its existence. However, Computed 
Tomography (CT) and Magnetic Resonance Imaging (MRI) yielded clues for the 
concept of vascular parkinsonism.163'166 Recently, we showed that patients clinically 
suspected of vascular parkinsonism (VP) indeed had more subcortical lesions (SCL) 
on MRI than both patients with Parkinson's disease (PD) and hypertensive controls 
already at risk for SCL.187 
Up to now, the EEG has rarely been used in studies to detect vascular ischaemic 
lesions as a cause of parkinsonism. In contrast with Parkes et al,139 who found a 
considerable excess of slow frequencies in 12 patients with vascular parkinsonism, 
Tolosa and Santamaria166 reported a normal EEG in their 2 patients with vascular 
parkinsonism. 
In PD, most conventional38,183 and quantitative132,154 EEG studies showed abnor­
malities in 35 to 50% of the cases. Slowing of the alpha rhythm and an increase of 
activity in the slower frequencies were reported. 
In unilateral cerebral ischaemia several variables were found to be abnormal.100 
The alpha rhythm may be diminished or, less frequently, enhanced in amplitude on 
the pathologic side. The presence of a frequency asymmetry of the alpha rhythm can 
be an important sign of local ischaemia since the lower frequency always indicates the 
pathologic side. Theta activity may occur in the parieto-temporal regions, which is 
generally interpreted as a slowed alpha rhythm. Furthermore, several types of delta 
activity in cerebral ischaemia have been mentioned by many authors: 1) diffuse delta 
68 Chapter 6 
activity over the ischaemic hemisphere; 2) local delta activity, in general most pro-
nounced in the anterior and mid-temporal regions, and 3) Frontal intermittent 
rhythmic delta activity (FIRDA) can occur especially when diencephalic structures are 
involved. 
Jonkman et al99 demonstrated that the neurometries method97 is a very sensitive 
approach for detecting abnormalities in the EEG of patients with unilateral ischaemia. 
This method of quantitative data evaluation uses multivariate techniques to compare 
the full profile of data for each patient with standardized data derived from a normal 
population. 
The objective of the present study is to investigate whether conventional EEG 
analysis and quantitative EEG analysis with neurometries can distinguish VP patients 
from patients with idiopathic PD. Therefore, it was explored whether: (1) VP patients 
score differently on a simple scale regarding aspects of conventional EEG variables 
than PD patients; (2) VP patients have less focal or diffuse EEG slowing than PD 
patients, and (3) VP patients have more EEG signs that are related with cerebral 
ischaemia than PD patients. 
METHODS 
Patients 
Fourteen PD patients and 13 VP patients were examined by EEG (table 1). PD was 
diagnosed in accordance with accepted clinical criteria.90 VP was diagnosed in patients 
60 years or older who had parkinsonism (hypokinesia and rigidity), dominated by 
frontal gait disorder,163 and who were not ruled out by the following exclusion criteria: 
resting tremor, neuroleptic therapy, brain trauma, supranuclear gaze palsy, cerebellar 
signs at onset, and orthostatic hypotension >30 mmHg.187 Patients with cognitive 
impairment, and other neurological diseases except Transient Ischaemic Attack (TIA) 
or Reversible Ischaemic Neurological Deficit (RIND) were excluded.187 MRI did not 
reveal a high SCL load in the PD patients, whereas all VP patients showed extended 
SCL as described in a previous study.187 The EEG was recorded at 8.30 a.m. after 
patients had breakfast. To reduce the effect of medication on the EEG regular 
levodopa, dopa-agonist and anticholinergic therapy had been discontinued for the 
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preceding 12-24 hours. In each patient group there were three patients who used 
benzodiazepines. These were discontinued three days preceding the day of examinati-
on. None of the patients used neuroleptics. In all cases informed consent was 
obtained prior to the examination in accordance with institutional guidelines. 
The severity of the clinical syndrome was expressed in gait velocity as gait disorder 
was the most prominent symptom in both our PD and VP patient groups. The velocity 
of gait during free-speed walking was assessed by measuring the time needed to cover 
a distance of ten meters. 
Table 1. Patient characteristics 
VP (n=13) 
Age (years) 72 ± 4 
Male/ female 10/ 3 
Disease duration 4 ± 3 
(years) 
Gait velocity 60 ± 23 
(cm/sec) 
NS = not significant (p*0.05). 
a: Student's t-test. 
b: Fisher's exact test. 
EEG recording and data analysis 
All EEG's were registered with a 21-channel Nihon-Kohden electroencephalograph 
type EEG-4421, using the international 10-20 system. The EEG was registered while 
the patient was resting (with the eyes closed) on a couch in a semi-darkened room. A 
filter setting of 0.15-30 Hz (-3dB) was used. 
For conventional EEG analysis the records were analysed by two experienced cli-
PD (n=14) significance level 
73 ± 7 NSa 
9/ 5 NSb 
7 ± 7 NS" 
63 ± 25 NS" 
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nical neurophysiologists (S.L.H.N. and J.W.P.) who did not have knowledge of the 
diagnosis. A scoring system was used (table 2)38 in which the following variables of the 
EEG were taken into account: 1) the frequency of the rhythmic background activity; 
2) the amount of diffuse slow activity; 3) the reactivity of the rhythmic activity; 4) the 
presence of paroxysmal activity; 5) the effect of rhythmic photic stimulation; 6) focal 
Table 2. Conventional assessment of the EEG 
(1) Frequency of rhythmic background activity 
0= >9.0 Hz 
1=8-9 Hz 
2= 7-8 Hz 
3=6-7 Hz 
4= 4-6 Hz 
5= None 
(2) Diffuse slow activity 
0= None 
1= intermittent theta 
2= intermittent theta + sporadic delta 
3= continuous theta + intermittent delta 
4= continuous theta + delta 
5= continuous delta 
(3) Reactivity of the rhythmic background activity 
0= normal reactivity 
1= diminished on eye opening 
3= absent on eye opening 
3= no reaction to somatosensory stimulation 
4= no reaction to auditory stimulation 
5= absence of all reactivity 
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(4) Paroxysmal activity 
0= None 
3= Paroxysmal slow activity 
5= FIRDA 
(5) Effect of rhytmic photic stimulation 
0= Normal driving 
1= Diminished driving 
2= Suppression only 
4= On-responses only 
5= No effect on photic stimulation 
(6) Focal disturbances 
0= No focal disturbances 
1= Mild disturbances unilateral 
2= Mild disturbances bilateral 
3= Severe unilateral and mild contralateral 
4= Severe bilateral 
5= Multifocal 
(7) Sharp wave activity (8) Grand total of EEG= (sum 1 - 7) + 1 
0= None 
2= Sporadic sharp waves 
3= Frequent sharp waves 
4= Triphasic waves 
5= Jakob-Creutzfeldt complexes or PLEDS 
abnormalities and 7) complex activity. For each of these variables a degree of abnor-
mality was scored on a 6-point scale (0-5) and, adding a constant (=1), summated to a 
total score (GTE score) ranging from 1 (perfect) to 36 (maximal abnormal). In those 
cases where disagreement between the two observers occured, the two scores were 
averaged. 
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For quantitative EEG analysis segments of at least 60 sec in duration without 
artefacts or signs of drowsiness were used for analog-digital conversion (sample rate 
128 Hz, 12 bits). 
In order to apply the neurometries method of data evaluation, 8 bipolar deriva­
tions were reconstructed from the original records with Cz as a common reference: 
F7-T3, F8-T4, T3-T5, T4-T6, СЗ-Cz, C4-Cz, P3-01, P4-02. For each bipolar deriva­
tion the absolute and relative (%) powers and mean frequencies were calculated for 
the following frequency bands: delta (1.5-3.5 Hz), theta (3.5-7.5 Hz), alpha (7.5-12.5 
Hz) and beta (12.5-25.0 Hz). Furthermore, power asymmetry was computed between 
homologous leads for each of the 4 frequency bands. These data were evaluated by 
the neurometries method as described in detail by John et al.97 In short, from the data 
of a reference group of normal volunteers the univariate features (relative power, 
etc.) and multivariate features (e.g. composites of z-values across different variables 
for one lead and composites of z-values for the same variable across several leads) 
were transformed to achieve gaussian distributions. Age-regression equations and the 
residual variance (ί) were computed for each transformed feature. To calculate the 
z-values of the data obtained from patients in this study, the age regression equations 
and residual variances of univariate and multivariate features computed from 64 
normal volunteers by Jonkman et al" were used. From our patient's data the multi­
variates overall all frequencies (OAF), overall all asymmetries (OAA) and the alpha 
band power asymmetry across the homologous derivations were calculated.97 OAF is 
the composite of the z-values of all relative band power values in all derivations. OAA 
is the composite of all band power asymmetries across all pairs of homologous deriva­
tions. In addition, EEG slowing (increase of relative delta and/or theta band power) in 
bipolar leads was calculated by neurometries. A z-value reaching the 5% criterion was 
considered as abnormal for all neurometrical variables.99 
Statistics 
In order to determine whether patient characteristics were significantly different 
between both patient groups, the t-test and the Fisher's exact test were used. Further­
more, the kappa values for inter-rater agreement between conventional EEG assesments 
EEG findings in patients with vascular parkinsonism 73 
of the two observers were calculated. Kappa coefficients are percentages of agree­
ment and may take values up to 1 (perfect agreement). To determine whether the 
conventional EEG variables were significantly different between both patient groups 
the t-test was used. Finally, to determine whether the neurometrical EEG variables 
were significantly different between both patient groups the Fisher's exact test and the 
Chi-Square test were used. In all test procedures p<0.05 was considered significant. 
RESULTS 
VP patients did not differ significantly from PD patients concerning age, sex, 
disease duration and gait velocity (table 1). 
The kappa values for inter-rater agreement between conventional EEG assess­
ments by the two observers for frequency of rhythmic background activity, diffuse slow 
activity, reactivity, paroxysmal activity, complex activity, focal abnormalities and effect 
of rhythmic photic stimulation were 0.86, 0.43, 0.17, 0.33, 0.47, 0.44 and 0.52 respecti­
vely. The inter-observer correlation for the total EEG score was 0.79. 
The conventional analysis of the EEG's showed significantly less abnormal (lower) 
scores for VP patients than for PD patients concerning the variables frequency of 
rhythmic background activity, diffuse slow activity, effect of rhythmic photic stimula­
tion and the grand total EEG score (all ρ < 0.05, table 3). The other conventional 
EEG variables (reactivity of rhythmic background activity, paroxysmal activity, focal 
abnormalities and sharp wave activity) were not significantly different between both 
groups. 
The neurometries analysis of the quantitative EEG data showed that the variables 
OAA, OAF, abnormal alpha band power asymmetry and increase of delta or theta 
band power activity were not significantly different between the two patient groups 
(table 4). However, the neurometries analysis showed significantly more slowing 
(increased relative delta and/or theta band power activity) in PD patients compared to 
VP patients in the following leads: F8-T4, T3-T5, T4-T6 and P4-02 (table 4). 
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Table 3. Conventional EEG parameters in VP patients compared to PD patients 
EEG-parameters 
Frequency of rhythmic 
background activity 
Diffuse slow activity 
Reactivity of the rhythmic 
background activity 
Paroxysmal activity 
Effect of rhythmic 
photic stimulation 
Focal disturbances 
Sharp wave activity 
Grand total of EEG 
VP (η = 13) 
Mean ± SD 
0.85 ± 0.83 
0.42 ± 0.40 
0.73 ± 0.53 
0.23 ± 0.56 
0.58 ± 0.81 
1.00 ± 0.89 
1.00 ± 0.82 
4.81 ± 3.13 
PD (n = 14) 
Mean ± SD 
1.68 ± 1.25 
1.11 ± 1.00 
0.93 ± 0.62 
0.82 ± 1.31 
1.54 ± 1.42 
1.61 ± 0.94 
1.46 ± 0.97 
9.18 ± 4.78 
significance 
level* 
p<0.05 
p<0.05 
NS 
NS 
p<0.05 
NS 
NS 
p<0.05 
* t-test; 
NS: not significant (p>0.05). 
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Table 4. Number (%) of VP patients compared to PD patients with abnormal scores 
for the variables obtained with quantitative EEG analysis and neurometries 
EEG-variables VP (n = 12) PD (n = 12) sign, level * 
abnormal alpha band power 
asymmetry: 
-F7-T3/F8-T4 3(25%) 0 (0%) NS 
-T3-T5/T4-T6 3(25%) 1 (8%) NS 
-P3-01/P4-02 1 (8%) 2(17%) NS 
abnormal OAA: 
abnormal OAF: 
3 (25%) 
5 (42%) 
3(25%) 
8 (67%) 
NS 
NS 
presence of EEG slowing 
(increase of delta and/or theta 
band power activity): 
F7-T3 
F8-T4 
T3-T5 
T4-T6 
P3-01 
P4-02 
1 (8%) 
0 (0%) 
1 (8%) 
2 (17%) 
3(25%) 
3 (25%) 
4 (33%) 
5 (42%) 
7 (58%) 
9 (75%) 
8 (67%) 
9 (75%) 
NS 
p<0.05 
p<0.05 
p<0.05 
NS 
p<0.05 
OAF: overall all frequencies; OAA: overall all asymmetries 
NS: not significant (p¿0.05). * Fisher's exact test. 
DISCUSSION 
Our EEG data of PD patients are in accordance with those already described in 
the literature. Yeager et al183 and de Weerd et al38 in conventional EEG, and Neufeld 
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et al and Soikkeli et al in quantitative EEG studies all showed slowing of the 
alpha rhythm and an increase of activity in the slower frequencies in PD. The 
percentage of our PD patients that show EEG slowing (75%) is higher than the usual 
described (35-50%). This can be explained by the use of neurometries, by which the 
full profile of data in all leads can be overviewed easily. 
Analysis of the quantitative EEG data with neurometries as well as analysis of the 
conventional data shows that VP patients had less EEG slowing (less delta and theta 
power, and less slowing of the alpha rhythm) than PD patients. The first method also 
shows that EEG slowing in PD is present in almost all bipolar leads, and especially in 
the mid-temporal and posterior temporal leads. These differences were neither 
influenced by a difference in age or disease severity as expressed in gait velocity, nor 
by the use of levodopa or anticholinergic medication in the PD group. Levodopa 
therapy may lead to a reduction of slow activity and an increase in alpha activity.70 
Also, anticholinergic medication does not lead to alpha slowing.120 In contrast with our 
results, Parkes et al139 reported an increase of slow frequency activity in patients with 
vascular parkinsonism, probably because their VP patients were more severely 
affected than our group. In contrast with our patients, many of their patients had 
pseudobulbar palsy, spastic dysarthria and emotional lability and some of them even 
had moderate dementia. 
VP patients did not have more EEG signs that are related with ischaemia than 
PD patients, neither detected by conventional EEG analysis (focal disturbances), nor 
by quantitative EEG analysis evaluated by the neurometries method as used by 
Jonkman et al99 in patients with unilateral ischaemia (alpha band power asymmetry, 
and abnormal OAF, OAA values). Of all quantitative EEG variables that are related 
with ischaemia, only OAF values were more abnormal in VP patients (42%) compa-
red to the control population (5% criterion, see method section). 
The bilateral location of SCL on the MRI scans of the VP patients187 could 
possibly explain that the alpha asymmetry variables and OAA were not more 
abnormal in VP patients compared to the control population (5% criterion, see 
method section) and the PD patients. Furthermore, there is probably no chronic 
ischaemia in patients with vascular parkinsonism. In a previous study with proton 
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magnetic resonance spectroscopy in VP patients we could neither detect metabolic 
signs of chronic ischaemia (increased lactate) in the deep white matter, nor in the 
striatum.186 The abnormal OAF values in VP patients probably represents post-ischae-
mic neuronal cell loss instead of ischaemia itself. 
Thus, this study shows that EEG can distinguish patients with vascular parkinso-
nism from patients with idiopathic Parkinson's disease. Unexpectedly, the VP patients 
showed less slowing of the alpha rhythm and less relative power in the slower 
frequencies than the PD patients. This indicates that VP patients are not PD patients 
with subcortical vascular lesions. VP patients did not show more EEG signs that are 
related with ischaemia than PD patients. 

CHAPTER 7 
MRS to detect degeneration of the substantia nigra 
in idiopathic Parkinson's disease 
Zijlmans JCM, de Koster A, Thijssen HOM, Horstink MWIM, Heerschap A 
Submitted for publication 
INTRODUCTION 
MRS seems to differentiate multiple system atrophy (MSA) from PD by showing 
a reduced ratio for the methyl signals of the metabolites N-acetylaspartate (NAA) 
and creatine (Cr) in the lentiform nucleus in MSA; whereas NAA/Cr ratios are 
normal in the PD group.34 NAA is an aminoacid which is almost entirely confined to 
neurons.128 Therefore, this decreased NAA/Cr ratio in the striatum of MSA patients 
likely reflects neuronal cell loss in this region.34 The goal of the present study was to 
evaluate the NAA/Cr level in the substantia nigra area of patients with PD, the main 
locus of neuronal degeneration in PD.53 
METHODS 
We used MRS centered on the substantia nigra in 9 patients with clinically 
definite PD90 (mean age 62.4 ± 8.8 years, duration of disease 7 ± 3 years). Their 
UPDRS subscore for rigidity was 2.3 ± 0.9 and for tremor 1.4 ± 0.7, on medication. 
We used 9 non-diseased controls (mean age 61.0 ± 9.3 years). 
MRI and MRS were done on a 1.5 tesla Siemens Magnetom with a standard 
circular polarized head coil. T2-weighted coronal and transversal images were made 
to select the volume of interest (figure 1). The substantia nigra constituted ±50% of 
the volume of interest (1.5x1.5x1.5 cm3). The nucleus ruber was selected partially to 
supplement the other ±50%. This volume of interest was located contralateral to the 
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Figure 1. T2-weighted transversal and coronal images showing the volume of interest centered 
on the substantia nigra. 
most severely affected side of the body. MR spectra were acquired with a double 
spin echo sequence including EXORCYCLE phase cycling.12 Technical variables: TR 
1,600 msec, TE 75 msec, 512 acquisitions. Data processing included zero-filling of the 
free induction decay to 4K data points, exponential multiplication, Fourier transfor-
mation and phase correction. Peak area ratios of NAA and Cr methyl signals were 
evaluated blind of diagnosis by computer integration of peak areas. 
RESULTS 
In general, shimming of the substantia nigra area was not a problem despite the 
assumed presence of accumulated iron in this region.45 
Phantom studies were performed to test the adequacy of the MRS pulse 
sequence for volume selection. Using water solutions of NAA at different concentra-
tions within the biological range we found an excellent linearity of the NAA signal 
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with selected volume size from 27 cc down to 3.4 cc. Furthermore, contamination by 
signals from outside the selected volume was less than 10%. 
To investigate the influence of small changes in the position of the sensitive 
volume, we obtained MR spectra of different volume sizes centered on the substantia 
nigra in three neurologically non-diseased controls (52 ± 16 years). The volume sizes 
varied from 1.5x1.5x1.5 cm3 to 2.3x2.3x2.3 cm3. The mean NAA/Cr ratio in the largest 
volume of interest in the three controls was 0.08 higher than in the smallest volume 
of interest. 
Figure 2 shows a spectrum of a PD patient with a reduced NAA/Cr ratio com-
pared to a healthy control. The mean NAA/Cr ratio in the PD group was significantly 
lower than in the controls (figure 3). 
NAA 
control 
v'^Htf^ 
Parkinson's disease 
PPM 
Figure 2. Proton MRS of substantia nigra area. Top= 59 year-old healthy woman. Lower= 70 
year-old man with PD. Methyl hydrogen signals are indicated. 
NAA= N-acetylaspartate; Cr= creatine; Cho= choline. 
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Figure 3. The mean NAA/Cr ratio in the PD group (1.27 ± 0.21) was significantly lower than in 
the controls (CS) (1.67 ± 0.37) (two-tailedρ = 0.022, Mann-Whitney test). 
DISCUSSION 
NAA/Cr signal levels in the substantia nigra area of the PD patients were 
significantly lower than in the controls. We only selected PD patients without severe 
tremor to avoid any differences between patients and controls caused by movement 
artefacts. The water spectral line width in all evaluated MR spectra was equal to or 
below 7 Hz; indicating the absence of disturbing movements. One could expect that 
the exact anatomical contents of the sensitive volume was systematically different 
between controls and some of our PD patients who maintained their necks in a 
slightly flexed posture. Control measurements in which volume sizes varied from 3.4 
up to 12.2 cm3 indicated that the small changes in the position of the sensitive 
volume did not significantly influence our results. 
We conclude that a decreased NAA/Cr ratio in PD likely reflects neuronal cell 
loss in the substantia nigra, as documented in postmortem studies.53 MRS might 
become an important tool in the diagnosis of PD and in studies on neuro-protection, 
because this non-invasive method may monitor neuronal cell loss. In the future, 
reduction of the partial volume effect may improve the diagnostic sensitivity of MRS. 
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CHAPTER 9 
GENERAL DISCUSSION 
We have tried to elucidate the question about the existence of vascular parkinso-
nism by challenging it on multiple levels. Therefore, we used MRI, MRS, quantitative 
EEG and gait analysis. This is the first time ever that subcortical lesions in patients 
clinically suspected of vascular parkinsonism (SVP) have been evaluated in a 
systematic way with control patients known to have vascular risk factors. In this study, 
MR images of patients suspected of vascular parkinsonism are not only compared 
with MR images of patients with Parkinson's disease (PD), but also with those of 
hypertensive controls. For this purpose, the volume of subcortical lesions was 
determined by a stereological method (instead of using a semiquantitative rating 
scale), giving a reliable and valid estimator of the total subcortical lesion volume. 
Our MRI study supports the concept of vascular parkinsonism. SVP Patients had 
a significantly higher subcortical lesion volume than PD patients, indicating that SVP 
patients are also radiologically distinguishable from PD patients. Furthermore, SVP 
patients also had significantly more SCL than a group of neurologically normal hyper-
tensive elderly. This suggests a causal relationship between SCL and parkinsonism in 
our SVP patients. Older persons without vascular risk factors may not serve as a 
control group, because of the probability of their having a lower SCL volume than 
our SVP patients, who were not selected because of absence of vascular risk factors. 
PD patients are also not an optimal control group. They might have less vascular risk 
factors than usual145 healthy individuals.66,158 
In SVP patients SCL were diffusely located mainly in the watershed areas, as was 
also reported by others.31,57,163 The differentiation of vascular parkinsonism in two 
types on the basis of their stage of onset and location of subcortical lesions (a chronic 
onset type with lesions located in the white matter, and an acute onset type with 
lesions located also in the gray matter) has not been described before. Probably, 
there are more types of vascular parkinsonism in which other locations are involved, 
for example types resembling progressive supranuclear palsy42,178 or multiple system 
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atrophy. 
This study also shows that gait analysis and EEG can distinguish patients with 
vascular parkinsonism from patients with idiopathic Parkinson's disease. VP patients 
have a more preserved arm swing, more (i.e. normal) anteflexion of the shoulder on 
the forward arc of the arm swing than PD patients. Leg and truncal movements in 
VP patients are less well preserved than arm movements. Unexpectedly, VP patients 
showed less slowing of the alpha rhythm and less relative power in the slower fre-
quencies than the PD patients. This indicates that VP patients are not PD patients 
with subcortical vascular lesions. VP patients did not show more EEG signs that are 
associated with ischaemia than PD patients. 
To prove the accuracy of clinical symptoms and subcortical MRI lesions in the 
diagnosis of vascular parkinsonism, post-mortem examination studies of SVP patients 
are necessary. 
Many authors stated that the clinical significance of subcortical lesions depends 
upon both severity and location of lesions.79,143,172 We confirmed the findings of Rao 
et al143 and Boone et al13, who concluded that a "threshold" extent of SCL may be 
necassary before symptoms are seen. Mesulam124 suggested that "a frontal lobe 
syndrome can be expected in cases where multifocal partial lesions (none of which 
are individually severe enough to disrupt specific cognitive domains such as language 
or memory) collectively undermine internetwork coordination". We concluded that 
subcortical lesions in the elderly, with or without parkinsonism, are diffusely distribu-
ted in the watershed zones, as was reported by Lechner et al,114 Kobayashi et al108 
and Horikoshi et al88 in their studies with non-diseased elderly. Research is needed to 
investigate why one patient with SCL gets vascular parkinsonism while others do not. 
We could not detect metabolic signs of ischemia (increased lactate) in deep white 
matter or in the striatum.22 Vascular parkinsonism is probably due to multiple acute 
ischemic micro-infarcts resulting in neuronal cell loss, while later on, lactate normali-
zes by diffusion and active transport and mechanisms appear that compensate the 
decreased oxygen supply resulting from decreased circulation.123 
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MRS might become an important tool in distinguishing patients with PD from 
those with VP and other types of parkinsonism, because this non-invasive method 
might monitor neuronal cell loss in the substantia nigra area as documented in 
postmortem studies.53 In the future, reduction of the partial volume effect might 
improve the diagnostic sensitivity of MRS. 
like Binswanger's disease, vascular parkinsonism probably should not be con-
sidered a distinct disease entity. The condition is almost certainly an ischemic 
disorder of the cerebral white matter that has diverse causes and pathofysiologies. 
Research is needed to evaluate possible etiologies and treatments. 

SUMMARY 
This thesis tries to clarify whether patients clinically suspected of vascular parkin-
sonism can be distinguished from patients with idiopathic Parkinson's disease, and 
whether vascular ischemic lesions can be detected in the former patient group. 
Chapter 1 gives a review of the discussion about vascular parkinsonism, subcorti-
cal lesions on CT/MRI and Binswanger's disease. 
In Chapter 2, the objective of the present magnetic resonance spectroscopy 
(MRS) study was to detect metabolic signs as a reflection of ischemic lesions in the 
brains of patients with clinical features of vascular parkinsonism. Proton MRS of the 
brain was performed in 12 patients suspected of vascular parkinsonism on clinical 
grounds as well as ischemic score, and also in a control group of 15 patients with 
idiopathic Parkinson's disease. The MR spectra were measured in the striatum and 
deep white matter, the main locations of SCL. MRS did not demonstrate metabolic 
evidence for the existence of ischemia (elevated lactate) or cell loss (decreased N-
acetyl-aspartate levels) in patients suspected of vascular parkinsonism. Several 
explanations for our findings are discussed. 
The severity of SCL has to be properly quantified in order to determine their 
clinical significance. In Chapter 3 a MR imaging quantification method for determi-
nation of absolute volumes of both subcortical white and gray matter lesions (SCL) 
and ventricular cerebrospinal fluid (VCSF) in living human brain tissue is described, 
and the method's reliability is determined. In 12 subjects absolute SCL and VCSF 
volumes were estimated using systematic sampling. Systematic sampling was perfor-
med on equidistant MR-slices using a counting grid with systematically ordered 
intersection points. The grid was randomly positioned on each consecutive MR-sIice. 
Each grid intersection point hitting the structure of interest represented a fixed 
known volume dependent on grid intersection point distance and the sum of slice 
thickness and slice gap. Absolute volume estimation of SCL and VCSF took 15 and 5 
minutes per subject, respectively. Coefficients of error of the individual volume esti-
mates ranged from .01 to .13, and were neglegible to the coefficients of the group 
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mean (range 0.69 to 0.89). For SCL volume the random intraobserver error yielded 
0.04 and for VCSF 0.02, the random interobserver error amounted to 0.11 and 0.04, 
and the systematic interobserver error was 0.1S and 0.04. It was concluded that the 
method described here for SCL and VCSF volume estimation is accurate, reliable, 
valid and fast. 
To determine whether MRI can reveal more vascular lesions in patients clinically 
suspected of vascular parkinsonism, we compared IS such patients with IS patients 
who had idiopathic Parkinson's disease (PD) and 10 hypertensive controls (Chapter 
4). Patients suspected of vascular parkinsonism had significantly more subcortical 
lesions than those with PD or hypertension. The cut-off point for the volume of sub-
cortical lesions to distinguish patients suspected of vascular parkinsonism from 
patients with PD was involvement of 0.6% of brain tissue volume. There were two 
types of vascular parkinsonism: one presented with an insidious onset and lesions 
diffusely distributed in the watershed areas; the other had an acute onset and lesions 
located also in the subcortical gray nuclei (striatum, globus pallidus, thalamus). 
The purpose of the study presented in Chapter 5 was to investigate whether 
quantitative gait analysis can differentiate between the gait pattern of patients with 
VP and the gait pattern of patients with idiopathic Parkinson's disease (PD). Twelve 
VP patients, 12 PD patients and 10 neurologically non-diseased controls were 
examined by quantitative gait analysis. VP patients showed relatively preserved arm 
swing with especially more anteflexion in the shoulder on the forward sway of the 
arm swing than PD patients for the same gait velocity and stride length. VP patients 
also showed less flexion dystonic posture of the elbow, hip, knee and trunk than PD 
patients. There was no significant difference in the excursions and coordination of 
arm swing in the VP patients compared to the control group. Both patient groups 
showed reduced leg movements, reduced hip extension and reduced knee flexion and 
extension as compared to the controls. 
The objective of the study in Chapter 6 was to investigate whether conventional 
EEG and quantitative EEG with neurometries can distinguish between patients with 
vascular parkinsonism and patients with idiopathic Parkinson's disease. Therefore, the 
EEG's of 13 patients with vascular parkinsonism and 14 patients with idiopathic 
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Parkinson's disease were examined. The patients with vascular parkinsonism showed 
less EEG abnormalities than the patients with idiopathic Parkinson's disease. 
Proton magnetic resonance spectroscopy (MRS) might become an important tool 
to distinguish patients with PD from those with VP. MRS can measure methyl signals 
of the metabolite N-acetylaspartate (NAA). A decrease in NAA may indicate 
neuronal cell loss. In Chapter 7, I describe our detection of a lower mean ratio for 
methyl signals of NAA and Creatine (Cr) in the substantia nigra area of nine patients 
with idiopathic Parkinson's disease (PD) compared to nine age-matched controls. 
This decreased NAA/Cr ratio most likely reflects neuronal cell loss in the substantia 
nigra. 

SAMENVATTING 
De onderzoeken beschreven in dit proefschrift trachten op te helderen of 
patiënten die klinisch verdacht zijn voor vasculair parkinsonisme te onderscheiden 
zijn van patiënten met de ziekte van Parkinson. Tevens werd nagegaan of er in de 
hersenen van de eerste patiëntengroep vasculaire ischemische laesies waargenomen 
kunnen worden. 
Hoofdstuk 1 geeft een overzicht van de discussie rond vasculair parkinsonisme, 
subcorticale CT en MRI laesies, en de ziekte van Binswanger. In dit hoofdstuk 
bespreek ik ook de incidentie van subcorticale CT en MRI laesies in verschillende 
patient- en leeftijdgroepen, hun klinische significantie, hun relatie met vasculaire 
risicofactoren, hun pathologische correlaten, de hemodynamische en metabole 
significantie van subcorticale laesies, hun Pathogenese, differentiële diagnose en 
mogelijke behandeling. Verder bespreek ik EEG studies van patiënten met subcorti-
cale laesies. 
Het doel van de studie met magnetische resonantie spectroscopie (MRS) in 
Hoofdstuk 2 was het detecteren van metabole afwijkingen als tekenen van ischemi-
sche laesies in de hersenen van patiënten met klinische verschijnselen van vasculair 
parkinsonisme. Proton MRS van de hersenen werd verricht in 12 patiënten verdacht 
van vasculair parkinsonisme op klinische gronden en een ischaemie score, en in een 
controle groep van 15 patiënten met de ziekte van Parkinson. De MR spectra 
werden afgenomen in het striatum en de diepe witte stof, de locaties waar zich de 
meeste subcorticale laesies bevinden. Met MRS konden we geen metabool bewijs 
voor het bestaan van ischaemie (verhoogd lactaat) of celverlies (verlaagd N-acetylas-
partaat spiegels) in patiënten verdacht van vasculair parkinsonisme verkrijgen. 
Verschillende verklaringen voor onze bevindingen werden besproken. 
Om de klinische relevantie van subcorticale laesies op te helderen moest eerst de 
uitgebreidheid van deze laesies goed bepaald kunnen worden. Het doel van de studie 
in Hoofdstuk 3 was een MRI quantificatie methode te beschrijven voor het bepalen 
van absolute volumina van zowel subcorticale witte en grijze stof afwijkingen (SCL) 
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als ventriculaire liquor ruimte (VCSF) in levende mensen hersenen, en het bepalen 
van de betrouwbaarheid van de methode. De absolute SCL en VCSF volumina in 12 
personen werden berekend met een systematische steekproef methode. Deze 
steekproef methode werd uitgevoerd m.b.v. systematisch gekozen MR-scans en een 
tel-rooster met systematisch geordende punten die op gelijke afstand van elkaar 
gelokaliseerd waren. Het rooster werd ad random gepositioneerd op elke achtereen-
volgende MR-scan. Elk punt op het tel-rooster dat één van de bovengenoemde 
structuren raakt representeert een vaststaand volume dat afhankelijk is van de 
afstand tussen elk punt en de som van elke scan dikte en scan tussenruimte. Gecon-
cludeerd mocht worden, dat de hierboven beschreven methode voor SCL en VCSF 
volume bepaling accuraat, betrouwbaar, valide en snel uitvoerbaar is. 
In Hoofdstuk 4 bestudeerden we of MRI meer vasculair laesies laat zien in 15 
patiënten die klinisch verdacht zijn van vasculair parkinsonisme dan 15 patiënten met 
de ziekte van Parkinson (PD) en 10 personen met hypertensie. Patienten verdacht 
van vasculair parkinsonisme hadden significant meer subcorticale laesies dan 
patiënten met PD of hypertensie. Het aangedaan zijn van 0.6% van het gehele 
hersenweefsel volume bleek een goed onderscheid te maken tussen patiënten 
verdacht van vasculair parkinsonisme en patiënten met PD. Er waren twee typen 
vasculair parkinsonisme: één die zich presenteerde met een sluipend onstaan en 
laesies diffuus verspreid over de waterscheidings gebieden; de ander had een acuut 
onstaan en laesies gelokaliseerd ook in de subcorticale grijze kernen (striatum, globus 
pallidus, thalamus). 
Het doel van de studie gepresenteerd in Hoofdstuk 5 was het onderzoeken of 
quantitatieve loop analyse kan differentiëren tussen het looppatroon van patiënten 
met VP en het loop patroon van patiënten met de ziekte van Parkinson. Twaalf VP 
patiënten, 12 PD patiënten en 10 neurologisch gezonde controles werden onderzocht 
met een quantitatieve loop analyse. VP patiënten toonden een relatief onaangedane 
armzwaai met vooral meer anteflexie in de schouder tijdens het voorwaardse deel 
van de armzwaai dan PD patiënten met dezelfde loopsnelheid en paslengte. VP 
patiënten toonden ook een minder flexie dystone houding van de ellebogen, heupen, 
kniëen en romp dan PD patiënten. Er was geen significant verschil tussen de uitwij-
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king en coördinatie van de armzwaai in de VP patiënten vergeleken met de controle 
groep. Beide patient groepen toonden afgenomen bewegingsuitslagen met de benen, 
verminderde heup extensie en verminderde knie flexie en extensie vergeleken met de 
controles. 
Het doel van de studie in Hoofdstuk 6 was het onderzoeken of conventionele 
EEG en quantitatieve EEG met neurometries analyse patiënten met vasculair 
parkinsonisme kan onderscheiden van patiënten met de ziekte van Parkinson. 
Hiervoor werden de EEG's van 13 patiënten met vasculair parkinsonisme en 14 
patiënten met de ziekte van Parkinson onderzocht. De patiënten met vasculair 
parkinsonisme toonden minder EEG afwijkingen dan de patiënten met de ziekte van 
Parkinson. 
Proton magnetische resonantie spectroscopie (MRS) kan mogelijk een belangrijk 
diagnostisch middel worden om patiënten met de ziekte van Parkinson te onderschei-
den van die met vasculair parkinsonisme. Proton magnetische resonantie spectro-
scopie (MRS) kan methyl signalen van de metaboliet N-acetylaspartate (NAA) 
meten. Een afname in NAA geeft waarschijnlijk neuronaal cel verlies weer. In 
Hoofdstuk 7, wordt de detectie van een lagere ratio voor methyl signalen van NAA 
en Creatine (Cr) in de substantia nigra regio beschreven van negen patiënten met de 
ziekte van Parkinson (PD), vergeleken met negen gezonde leeftijdgenoten. Deze 
verlaagde NAA/Cr ratio weerspiegelt waarschijnlijk neuronaal cel verlies in de 
substantia nigra. 
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STELLINGEN 
1. Het concept 'Vasculair parkinsonisme" dient te worden gehandhaafd. 
(dit proefschrift) 
2. Er kunnen (minstens) twee vormen van "vasculair parkinsonisme" onderschei-
den worden: één die zich presenteert met een sluipend ontstaan en laesies 
diffuus verspreid over de waterscheidingsgebieden, de andere met een acuut 
begin en laesies gelokaliseerd ook in de subcorticale grijze kernen. 
(dit proefschrift) 
3. Om de nauwkeurigheid van de diagnose 'Vasculair parkinsonisme" te verbete-
ren is post-mortem onderzoek van patiënten verdacht van 'Vasculair parkin-
sonisme" onontbeerlijk. 
(dit proefschrift) 
4. Bij patiënten met 'Vasculair parkinsonisme" is de armzwaai tijdens het lopen 
minder afwijkend dan bij patiënten met de ziekte van Parkinson. Dit blijkt uit 
een nagenoeg normale anteflexie van de schouder tijdens de voorwaartse 
armbeweging. 
(dit proefschrift) 
5. De EEG's van patiënten met 'Vasculair parkinsonisme" vertonen duidelijk 
minder vertraging van het alpha ritme en minder toename in activiteit van de 
lage frequenties dan die van patiënten met de ziekte van Parkinson. Dit wijst 
er (nogmaals) op dat patiënten met 'Vasculair parkinsonisme" niet Parkinson 
patiënten met toevallig subcorticale vasculaire laesies zijn. 
(dit proefschrift) 
Veel onderzoeken betreffende het ouder worden zijn verkeerd opgezet 
geweest, omdat bij het samenstellen van de zogenaamde "normale" controle-
groepen geen rekening is gehouden met de aanwezigheid van eventuele risico-
factoren voor de te onderzoeken afwijkingen. 
(Rowe JW and Kahn RL. Science 1987;237:143-149) 
Voor Angelsaksische auteurs van medisch wetenschappelijke literatuur geldt 
vaker "wie schrijft, die blijft", daar zij gemakkelijker artikelen gepubliceerd 
krijgen dan hun niet-engelstalige collega's. 
De halfwaardetijd van een wetenschappelijk artikel op de science citation index 
is aanzienlijk korter dan die in de archiefkasten van de meeste onderzoekers. 
Indien een patient zich meldt bij de KNO-arts met een neusseptum perforatie, 
dient de behandelaar "white matter lesions" in zijn differentiaal diagnose te 
betrekken. 
Juist in het digitale tijdperk is het van belang er één te blijven en geen nul te 
worden. 
In onze maatschappij wordt iemand met een passie te vaak als geobsedeerd 
beschouwd. 
De Sagrada Familia dankt zijn bestaan aan afschuw voor zwart-wit denken. 
(zie kaft-tekening) 


